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Neisseria gonorrhoeae is the causative bacteria of the sexually transmitted infection (STI), 
gonorrhoea. Rapid emergence of antibiotic resistant strains of N. gonorrhoeae has given 
rise to almost untreatable gonorrhoea over the last few decades. There is an urgent need 
for development of new antimicrobial treatments for gonorrhoea infection. Synthesis of 
the amino acid cysteine is a promising new target for the development of new 
antimicrobials. Cysteine plays a vital role in protein folding and function, and synthesis 
of glutathione for protection against oxidative stress during infection.  
 
The final step of the two-step cysteine biosynthesis pathway is catalysed by the enzyme 
O-acetylserine sulphydrylase (OASS). Most bacteria have two isoforms of OASS, 
OASS-A/CysK that utilises sulphide and O-acetylserine for the synthesis of cysteine and 
OASS-B/CysM that utilises thiosulphate. N. gonorrhoeae has just one OASS isoform 
(annotated as CysK) in its genome. N. gonorrhoeae displays unique differences in its 
sulphate acquisition pathway for cysteine biosynthesis, yet little is known about these 
pathways in N. gonorrhoeae. We propose CysK is a potential antimicrobial target. This 
thesis biochemically characterises the structure and function of CysK to determine its role 
in cysteine biosynthesis. Kinetic characterisation demonstrates that CysK has 
O-acetylserine sulphydrylase activity and displays positive cooperativity with respect to 
substrates, O-acetylserine and sulphide. Sulphide shows partial allosteric inhibition, and 
the enzyme does not use thiosulphate as a substrate. The structure of CysK was solved to 
2.49 Å by X-ray crystallography and shows CysK belongs to the tryptophan synthase β 
superfamily and adopts a homodimeric structure consisting of two monomers. The 
structure supports positive cooperativity as co-factor binding residues are in inactive and 
active conformations in each monomer of the dimer, respectively. Many CysK enzymes 
form complexes with the first enzyme in the two-step cysteine synthesis pathway, CysE. 
It appears CysE and CysK from N. gonorrhoeae are unable to form a complex, indicating 
an alternate pathway for regulation of sulphur flux and cysteine production. Attempts to 
investigate the in vivo role of CysK were inconclusive. 
 
The research presented in this thesis represents a major leap in our understanding of the 
uncharacterised cysteine biosynthesis pathway in N. gonorrhoeae. Data presented here is 
the basis for future work using the kinetics and structure of CysK to guide computational 
inhibitor design, to identify lead compounds for CysK inhibition, and thereby 
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Neisseria gonorrhoeae is the causative agent of the sexually transmitted infection (STI) 
gonorrhoea (Hill et al., 2016; Wi et al., 2017). N. gonorrhoeae is a Gram-negative, 
diplococcus (referred to as gonococcus, GC), obligate human pathogen primarily 
transmitted through sexual contact (Hill et al., 2016). Records of the contagious nature of 
N. gonorrhoeae can be seen in biblical times, indicating gonorrhoea to be one of the oldest 
recorded human diseases (Edwards & Apicella, 2004). More than 60 million cases of 
gonorrhoea were reported annually in 1996 (Gerbase et al., 1998), with numbers 
increasing to an estimated over 85 million cases worldwide in 2016, making it the third 
most prevalent STI worldwide (Rowley et al., 2019). Alongside this, an increasing 
number of strains have developed antimicrobial resistance (AMR) to every available 
antibiotic used for its treatment (Wi et al., 2017). Due to the combination of both 
increasing prevalence and increasing AMR, the World Health Organisation (WHO) has 
labelled N. gonorrhoeae as a high priority pathogen (WHO, 2017). All three of these 
factors have created an increased demand for the development of new antimicrobial 
agents to treat this disease in the future. Targeting and prevention of amino acid 
biosynthesis in bacteria is one such new and promising avenue for this development. The 
amino acid cysteine is not only crucial for protein folding and function, and protection 
from oxidative stress during infection, but its biosynthesis is the primary pathway for 
sulphur acquisition in bacterial cells (Hatzios & Bertozzi, 2011; Takumi & Nonaka, 2016; 
Ren et al., 2017; Anderson et al., 2019). Therefore, making cysteine biosynthesis a 
promising target for development of new antimicrobial drugs. This pathway, however, 
remains uncharacterised in N. gonorrhoeae. This research investigates the enzyme CysK 
O-acetylserine sulphydrylase (CysK), which is involved in the final step of cysteine 
biosynthesis, as a potential antimicrobial target in N. gonorrhoeae.    
1.2 Pathogenesis of Gonorrhoea 
N. gonorrhoeae has evolved alongside humans for millennia, resulting in its host 
restriction to humans, and thus its obligate human pathogenicity (Landig et al., 2019). 
The ability of N. gonorrhoeae to mitigate host immune responses through a variety of 
mechanisms heavily contribute to its pathogenic success. N. gonorrhoeae infects a variety 
 
2 
of mucosal surfaces such as the urethra, the endocervix, the ectocervix, the nasopharynx, 
conjunctiva (inside of eyelids and the white surface of eyes) and the rectum with the 
urogenital epithelia (urethra, endocervix and ectocervix) being the most common sites of 
infection (Edwards & Apicella, 2004; Edwards & Butler, 2011; Hill et al., 2016; Wi et 
al., 2017; Landig et al., 2019; Rowley et al., 2019). It is also common for new-born babies 
to contract N. gonorrhoeae infection in their anus, nasopharynx and eyes from mothers 
with gonorrhoea (Sandstrom, 1987).  
 
Gonorrhoeal infection begins with colonisation of the mucosal membrane, via adhesion 
to the epithelial cells through four established adhesins; (1) the major outer membrane 
protein, porin, (2) two types of opacity-associated (Opa) proteins, Opa50 and Opa52, (3) a 
major glycolipid of the outer membrane of gonococcus (GC), lipooligosaccharide (LOS) 
which lacks the repeating O-antigen of lipopolysaccharide, and (4) long polymers of pilin 
proteins that protrude from the GC surface, type IV-A pili (Edwards & Butler, 2011). The 
mode of adhesion used by GC is dependent on specific cell type, site of infection, and 
gender (Edwards & Apicella, 2004). Once initial adhesion occurs, the gonococci begin to 
form micro-colonies on non-ciliated columnar epithelial cells 1 – 2 hours after infection 
(Hill et al., 2016). From this stage, the general process involves the pilus-mediated 
attachment of the GC to the CD46 host cell-surface receptors. This begins once the micro-
colonies reach a cell density of 100+ GC (Figure 1.1) (Hill et al., 2016). Tighter binding 
to the host cells is mediated via PilE depolymerisation of pilus structures which is 
followed by Opa binding to CEACAM receptors (Figure 1.1) (Hill et al., 2016). Actin 
polymerisation and rearrangement is induced within the host cells. This results in 
bacterial endocytosis into host cells, transcellular transcytosis or trafficking of bacteria to 
the basolateral side of cells where they are exocytosed into the subepithelial layer (Figure 
1.1) (Hill et al., 2016). GC isolated from the male urethra show co-expression of pili and 
at least one of several Opa proteins. In women however, Opa expression varies depending 
on the stage of the menstrual cycle, and the consumption of oral contraceptives (Hill et 
al., 2016). The adhesion process GC undertakes is thus dependent upon the nature of its 
host. In some infections, N. gonorrhoeae is able to remain inside mucosal cells, in a 




Figure 1.1: Schematic representation of a N. gonorrhoeae infection. (1) Piliated, Opa-expressing gonococci 
interact with the mucosal epithelium. The thin, hair-like pilus appendages provide the initial contact with 
receptors on the surface of the mucosal cells. (2) Pili are then retracted which allows for more intimate, 
Opa-mediated attachment of the bacteria with the CD66 antigens located on the mucosal cells. 
(3) Following Opa-mediated attachment, the bacteria are engulfed and are internalised into the mucosal 
cells. (4) Following internalisation, some bacteria can transcytose to the basolateral side of the mucosal 
epithelium. (5) Depending upon which Opa protein is being expressed, gonococci can also reside and 
survive inside of neutrophils. (6) Following transcytosis, gonococci can enter the bloodstream where heavy 
sialylation of lipooligosaccharide (LOS) renders the bacteria serum resistant. Figure from (Hill et al., 2016). 
Upon attachment to mucosal cells, or entrance into the sub-epithelial layer, an immune 
response is triggered (Hill et al., 2016). This immune response involves recruitment of 
pro-inflammatory cytokines and neutrophils to the infection site, leading to the observable 
symptoms of GC infection, localised inflammation and pustular discharge (Ramsey et al., 
1995; Fisette et al., 2003; Hill et al., 2016; Anderson et al., 2019). This initial infection 
causes uncomplicated cervicitis in women, and urethritis in men, both of which present 
observable symptoms and are local infections (Unemo & Shafer, 2014). However, in 
many cases, N. gonorrhoeae is in a persistent state, presenting an asymptomatic 
subclinical infection where no immune response is triggered (Workowski & Berman, 
2011). Asymptomatic subclinical infections result in persistent GC infection. This affects 
women disproportionately to men, occurring in 50% of cases compared to 10% 




Persistent bacteria are a subpopulation of bacteria that differentiate to become dormant 
and significantly decrease their rate of division (Kussell et al., 2005; Balaban, 2011). This 
improves the bacteria’s ability to survive environmental stresses such as nutrient 
starvation or antibiotic treatments (Kussell et al., 2005; Balaban, 2011). Bacteria in this 
persistent state have a higher tolerance to antibiotics as they downregulate the replication 
and division cellular processes that are targeted by antibiotics, sometimes completely 
avoiding antibiotic exposure (Lewis, 2010; Balaban, 2011; Maisonneuve & Gerdes, 
2014). This persistence is different to antibiotic resistant phenotypes, which prevent 
antibiotics from binding to their targets (Lewis, 2010). Once environmental stresses have 
attenuated, the dormant subpopulation can upregulate its cellular growth pathways, 
actively dividing, thus repopulating their environment (Balaban, 2011). 
      
Untreated asymptomatic GC infections can over time enter a carrier state. In the carrier 
state, apparently healthy individuals carry the disease and are able to transmit the 
infection, or it can allow GC to ascend into the upper urogenital tract leading to more 
complicated infections (Hopper et al., 2000; Edwards & Apicella, 2004; Edwards & 
Butler, 2011). Complications include pelvic inflammatory disease, salpingitis (acute 
inflammation of the fallopian tubes) and endometritis, all of which can lead to infertility 
or an ectopic pregnancy (where pregnancy occurs outside the uterus and is often life-
threatening) (Hopper et al., 2000; Fisette et al., 2003; Edwards & Apicella, 2004; 
Edwards & Butler, 2011; Rowley et al., 2019). In rare cases, certain strains are capable 
of dissemination, crossing the endothelium, resulting in septic arthritis, pustular skin 
lesions, and bacteraemia (presence of bacteria in the blood stream, which can cause 
serious harm to the body and spread to other organs) (Hopper et al., 2000; Fisette et al., 
2003; Edwards & Apicella, 2004; Hill et al., 2016; Rowley et al., 2019). Nasopharyngeal 
infections are of particular concern, due to their asymptomatic nature and hypothesised 
role as one of the main routes for acquisition of antimicrobial resistant genes (Unemo & 
Shafer, 2014). N. gonorrhoeae is naturally transformable, readily accepting DNA, such 
as antibiotic resistant plasmids, from the environment into its chromosome, even if these 
plasmids are present during periods of persistence (Ochman et al., 2000). The ability to 
naturally transform, plays a large role in the antigenic variation generated by 
N. gonorrhoeae. This allows evasion of the immune systems recognition of the pathogen, 
thus allowing multiple infections to occur in an individual over their lifetime (Stern et al., 
1986; Criss et al., 2005; Hill et al., 2016). 
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1.3 Surfacing of antibiotic resistant Neisseria gonorrhoeae 
 The WHO has labelled N. gonorrhoeae as a high priority pathogen due to the rapid 
surfacing of antibiotic resistant strains (WHO, 2017). N. gonorrhoeae has the highest 
levels of AMR across all STIs. Over the last 70 to 80 years, N. gonorrhoeae has become 
increasingly resistant to an extensive range of antibiotic classes including: 
fluoroquinolones, macrolides, sulphonamides, penicillins, tetracyclines, and early 
generation cephalosporins (Unemo & Shafer, 2014; Wi et al., 2017; Bodie et al., 2019). 
The only remaining empirical monotherapy for gonorrhoeal treatment is the injectable 
extended-spectrum cephalosporin (ESC) ceftriaxone. However, treatment failures and 
in vitro resistance to cefixime and ceftriaxone alongside high-level clinical resistance to 
all ESCs has been found in many countries (Unemo & Shafer, 2014; Wi et al., 2017). 
Combined with the possibility of N. gonorrhoeae developing AMR to any monotherapy 
antibiotic, it was thought that monotherapy was no longer an option (Unemo & Shafer, 
2014; Bodie et al., 2019; Unemo et al., 2020). Thus, to combat AMR development, 
particularly to ceftriaxone as the only effective monotherapy antibiotic, dual-therapy of 
the ESC ceftriaxone combined with the oral antibiotic azithromycin was recommended 
(Unemo & Shafer, 2014; Kidd & Workowski, 2015; Wi et al., 2017; Unemo et al., 2020). 
However, AMR to ceftriaxone and azithromycin is on the rise, on a global scale (Unemo 
& Shafer, 2014; Eyre et al., 2018; Fifer et al., 2018; Bodie et al., 2019; George et al., 
2019; Cyr et al., 2020). In 2018, strains of N. gonorrhoeae that were completely resistant 
to both ceftriaxone and azithromycin were isolated in the UK (Eyre et al., 2018; Jennison 
et al., 2019). These cases resulted in three days of hospitalisation with last resort 
intravenous antibiotic treatment for the patients. There have been no cases of treatment 
resistant gonorrhoea in New Zealand, however, ceftriaxone and azithromycin resistance 
have been detected in several district health boards (Lee et al., 2018). Antimicrobial 
susceptibility of 400 New Zealand N. gonorrhoeae was tested in a recent study, revealing 
around 4 and 10% of isolates had decreased susceptibility to ceftriaxone and azithromycin 
respectively (Lee et al., 2018). Combined with the increasing incidence of gonorrhoea 
infection in New Zealand and across the globe (Lee et al., 2018; Rowley et al., 2019), the 
possibility of ceftriaxone and azithromycin resistant gonorrhoea emergence in New 
Zealand is ever increasing.  
 
As a result of increasing evidence of strains resistant to dual-therapy and azithromycin in 
particular, the United States (US) Centre for Disease Control and Prevention (CDC) 
updated its treatment guidelines in 2020, recommending monotherapy with ceftriaxone 
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(Cyr et al., 2020). Subsequently, the ‘super-bug’ status, alongside N. gonorrhoeae’s 
labelling as a ‘high priority pathogen’ by the WHO demonstrates the urgent need for 
research to develop both vaccines to reduce the spread of gonorrhoea, and new 
antimicrobial agents for treatment of AMR gonorrhoea infections (WHO, 2017). New 
antimicrobial targets for the design of new antibiotics are in critical demand. One such 
approach, is targeting the pathways and mechanisms essential for infection and survival 
of N. gonorrhoeae.  
 
The sulphur assimilation and cysteine biosynthetic pathways play an integral role in 
survival of many persistent pathogens and as such provide a new and promising area for 
antimicrobial research (Campanini et al., 2014). This avenue has been investigated for 
development of antimicrobials for treatment of pathogens such as the tuberculosis causing 
bacterium, Mycobacterium tuberculosis, or the acute gastroenteritis causing bacterium, 
Salmonella typhimurium (Campanini et al., 2014). We hypothesise these pathways are 
also a valid target in N. gonorrhoeae.  
1.4 Oxidative stress and the role of L-cysteine in N. gonorrhoeae   
The primary method of environmental inorganic sulphur acquisition in almost all bacteria 
requires L-cysteine biosynthesis. Cysteine residues play a vital role in protein folding, 
structure and therefore function, through the disulphide bonds they form (Takumi & 
Nonaka, 2016). Cysteine is also used to form an array of vital biomolecules such as biotin, 
co-enzyme-A and iron sulphur clusters (Kredich, 2008; Takumi & Nonaka, 2016; Hicks 
& Mullholland, 2018). Cysteine is also utilised for producing reducing agents thioredoxin 
and glutathione, which are essential for mitigating intracellular oxidants (Carmel-Harel 
& Storz, 2000; Kredich, 2008; Hicks & Mullholland, 2018).   
 
One of the primary challenges for bacteria, in particular pathogenic bacteria, is surviving 
the hostile host environment and evading the host immune system, both of which 
N. gonorrhoeae is proficient in (Quillin & Seifert, 2018). N. gonorrhoeae inhabits an 
environment of unrelenting oxidative stress and is constantly under pressure of oxidative 
killing from the host (Seib et al., 2006). Thus, making mechanisms to mitigate this 
oxidative stress of extreme importance. There are two main sources of oxidative stress 
N. gonorrhoeae is exposed to; oxidative stress produced by commensal Lactobacillus 
species, and the host immune system. The immune system exerts this oxidative killing 
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mechanism primarily through polymorphonuclear neutrophils (PMNs) (Seib et al., 2006; 
Quillin & Seifert, 2018).  
 
Lactobacilli are one of the most prevalent micro-flora of the female urogenital tract 
(Larsen & Monif, 2001). Lactobacillus species have been shown to inhibit 
N. gonorrhoeae colonisation of the urogenital tract (Larsen & Monif, 2001; Seib et al., 
2006). Lactobacillus species secrete lactate, which lowers pH, promoting aerobic 
respiration, which leads to endogenous production of reactive oxygen species (ROS) 
(Seib et al., 2006). Lactobacilli also secrete hydrogen peroxide, which is shown to inhibit 
growth of N. gonorrhoeae at a more acidic pH (Larsen & Monif, 2001; Seib et al., 2006). 
It was also found that Lactobacillus and Candida species may co-colonise the female 
urogenital tract (Larsen & Monif, 2001). In addition, Candida species were found to 
produce gliotoxin, a substance that supresses the growth of N. gonorrhoeae (Hipp et al., 
1974; Larsen & Monif, 2001).  
 
Oxidative stress from the host immune system begins with colonisation of the surface of 
cell epithelia. During colonisation, N. gonorrhoeae releases outer membrane vesicles 
(OMVs) and LOS, which bind to nucleotide binding oligomerisation domain (NOD) and 
toll-like receptors (TLRs) on dendritic cells and macrophages (Fisette et al., 2003; Liu et 
al., 2006; Quillin & Seifert, 2018). Upon binding, a signalling cascade results in release 
of chemokines and cytokines (Fisette et al., 2003; Liu et al., 2006; Hill et al., 2016; 
Quillin & Seifert, 2018). Release of the cytokines recruits PMNs to the site of infection 
(Edwards & Apicella, 2004; Hill et al., 2016; Quillin & Seifert, 2018). PMNs 
phagocytose N. gonorrhoeae, using antibacterial peptides, proteases and neutrophil 
mediated oxidative burst (rapid release of ROS). The oxidative burst results in superoxide 
anion formation, which leads to further ROS (Seib et al., 2006; El-Benna et al., 2016; 
Quillin & Seifert, 2018). Phagocytosis is an effective method for killing most bacteria, 
however, N. gonorrhoeae has evolved the ability to survive this process, mitigating the 
oxidative burst and replicating within the PMNs (Simons et al., 2005). The purulent 
excretion, which is characteristic of gonorrhoea infection, is largely comprised of PMNs 
infected with N. gonorrhoeae (Hill et al., 2016). For N. gonorrhoeae to be capable of 
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mitigating this oxidative stress, an effective intracellular reducing system is required. 
Most of the compounds that comprise this system are derived from L-cysteine. 
 
One such compound is glutathione, which is synthesised by glutathione reductase. 
Glutathione’s role in the cell is to regulate the redox balance when encountering free 
radicals released by the host cell and to prevent unwanted oxidation of cellular contents 
(Meister & Anderson, 1983; Pinto et al., 2013). Therefore, glutathione levels are one of 
the main oxidative stress mitigating mechanisms encountered during infection. 
Glutathione synthesis systems are present in N. gonorrhoeae (Hicks & Mullholland, 
2018), however, there is a distinct lack of glutathione transportation systems (Seib et al., 
2006). Given the lack of transporters, glutathione synthesis in N. gonorrhoeae is 
dependent on the cysteine biosynthetic pathway (Hicks & Mullholland, 2018). 
1.5 Sulphate assimilation and cysteine biosynthesis in Neisseria species 
The de novo biosynthesis of L-cysteine has been extensively studied and is conserved 
across bacteria, protozoa and higher plant species (Mino & Ishikawa, 2003; Jeelani et al., 
2017). This is the main pathway for these organisms to acquire environmental inorganic 
sulphur (Nozaki et al., 1999; Jeelani et al., 2017). Neisseria meningitidis and 
N. gonorrhoeae share a large degree of genome similarity (90%) (Hicks & Mullholland, 
2018), however, there are key differences between these two pathogenic Neisseria species. 
Namely, sulphate acquisition and cysteine synthesis pathways, which will be discussed 
in this section. 
1.5.1 Active sulphate transport 
Cysteine biosynthesis begins with the import of sulphur into the cell, and subsequent 
reduction via the reductive sulphate assimilation pathway (RSAP) (Campanini et al., 
2014). There are two main families of sulphate transporter proteins responsible for the 
uptake of inorganic sulphate into microbial cells, the major facilitator superfamily (MFS) 
and the ATP-binding cassette (ABC) superfamily (Kertesz, 2001; Guédon & Martin-
Verstraete, 2007). These transporters actively import sulphate into the cell. Genomic 
analysis of pathogenic Neisseria species (N. meningitidis and N. gonorrhoeae) showed 
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that N. gonorrhoeae only has one sulphate uptake system, from the ABC transporter 
superfamily (Figure 1.2) (Hicks & Mullholland, 2018). 
 
Figure 1.2: Sulphate acquisition and cysteine biosynthetic pathways in Neisseria species. The sulphate 
reduction pathway absent in N. gonorrhoeae is shown in red. Red and black pathways are functional in N. 
meningitidis. Differences between Neisseria species and other bacterial species are shown by two dotted 
lines. Figure from (Hicks & Mullholland, 2018). 
This is composed of a transporter permease (cysW), an ATP-binding protein (cysA), 
periplasmic sulphate-binding protein (sbp) and a sulphate permease (cysU) (Kertesz, 
2001; Hicks & Mullholland, 2018). The sulphate permease (cysU) is present in both 
Neisseria species except for the FA1090 N. gonorrhoeae strain (Hicks & Mullholland, 
2018). The sbp transporter has previously been shown to transport sulphate (Kredich, 
2008) and given that N. gonorrhoeae is able to grow with thiosulphate as a sole source of 
sulphur (Le Faou, 1984), this indicates that sbp is able to transport thiosulphate in 
N. gonorrhoeae (Hicks & Mullholland, 2018).  
1.5.2 Sulphate Reduction 
After importation into the cell, sulphate is prepared for incorporation into L-cysteine 
through successive reduction of sulphide (Figure 1.2). In E. coli, sulphate is first reduced 
to adenosine 5’-phosphosulphate (APS1) by the multi-enzyme complex ATP 
sulphydrylase (CysDN) (Sekowska et al., 2000). In most bacteria, APS1 is reduced to 
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phosphoadenosylphosphosulphate (PAPS) by ATP-kinase (CysC), and is subsequently 
reduced by PAPS reductase (CysH), to sulphite and phosphoadenosylphosphate (PAP) 
(Sekowska et al., 2000; Kredich, 2008). However, in Neisseria species, both reduction of 
APS1 to PAPS, and subsequent reduction to PAP is carried out by a single enzyme, APS1 
reductase (which is also denoted as CysH). This is therefore a single step reaction from 
APS1 reduced directly to sulphite (Figure 1.2) (Rusniok et al., 2009). The final step of the 
sulphate reduction pathway involves reduction of sulphite to sulphide by the sulphite 
reductase (CysIJ) (Kredich, 2008). Sulphide is then incorporated with O-acetylserine to 
form L-cysteine (Figure 1.2).  
 
Genome analysis of Neisseria species revealed the variance in completeness and 
arrangement of the sulphate reduction pathway (Hicks & Mullholland, 2018). In 
N. meningitidis, both import and reduction genes are controlled by a single operon 
cysGHDNJI. However, in all N. gonorrhoeae strains examined by Hicks and Mullholland 
(2018), a 3.5 kb deletion between cysG and cysN genes, has removed cysH and cysD from 
this operon (Figure 1.3) (Hicks & Mullholland, 2018). These genes are not found 
anywhere else in the N. gonorrhoeae genome (Hicks & Mullholland, 2018). The sulphite 
reductase encoding genes, cysIJ, are present in the N. gonorrhoeae genome, however, 
they are non-functional due to an in-frame stop codon present in each coding sequence 
(Figure 1.3) (Hicks & Mullholland, 2018). cysD deletion would prevent N. gonorrhoeae 
from reducing sulphate to APS1, alongside cysH deletion preventing subsequent reduction 
of APS1 to sulphite. The in frame stop codons in cysIJ would prevent reduction of sulphite 
to sulphide. The combination of these deletions and in frame stop codons renders this 
pathway of sulphate reduction non-functional in N. gonorrhoeae. Investigation of the 
sulphur requirements of Neisseria species, demonstrated the inability of N. gonorrhoeae 
to grow on sulphate as its sole source of sulphur (Le Faou, 1984). This is consistent with 
the non-functional sulphate reduction pathway in N. gonorrhoeae described above. Other 
commensal species and some strains of N. meningitidis, however, can grow on sulphate 
as a sole sulphur source. Previous growth experiments demonstrated N. gonorrhoeae’s 
ability to grow on media supplemented with thiosulphate, in the absence of L-cysteine 
(Le Faou, 1984). The requirement for L-cysteine, being met by thiosulphate links to the 
non-functional sulphite reducing pathway and suggests that the ABC transporter complex 
is able to import both thiosulphate and sulphate (Hicks & Mullholland, 2018). 
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Figure 1.3: Comparison of the sulphate reduction operons from N. meningitidis and N. gonorrhoeae. 
Dotted lines show a deletion between cysG and cysN in N. gonorrhoeae, resulting in a deletion between 
cysG and cysN in N. gonorrhoeae. This causes deletion of cysH and cysD and the partial truncation of cysG 
and cysN. Direction of arrows indicates direction of transcription. Dashed lines show stop codons in 
pseudogenes of N. gonorrhoeae. Figure from (Hicks & Mullholland, 2018). 
1.5.3 L-Cysteine and L-Cystine transport 
It is well established that de novo cysteine biosynthesis is well conserved across bacteria 
and many other species, however, bacteria can also obtain L-cysteine directly from the 
environment. Under oxidative conditions, L-cysteine is more commonly found in its 
oxidised form L-cystine (a disulphide bond is formed between two L-cysteine molecules) 
(Korshunov et al., 2020). In Neisseria species, L-cysteine and L-cystine are actively 
imported into the cell via ABC-transporters. N. gonorrhoeae has ABC transporters for 
both L-cysteine (ngo2011-2014), and L-cystine (ngo0372-0374) (Figure 1.4) (Bulut et al., 
2012; Hicks & Mullholland, 2018). Interestingly, in N. meningitidis, homology searches 
of the genome showed the presence of only the L-cystine transporter nmb0786-0789 
(Figure 1.4). The cystine ABC transporter operon in N. meningitidis shows 97% identity 
to the ngo0372-0374 L-cystine ABC transporter operon indicating similar modes of 
cystine transport in both species (Hicks & Mullholland, 2018). N. gonorrhoeae and 
N. meningitidis genome comparisons (90% sequence homology), however, demonstrated 
complete deletion of the L-cysteine ABC transporter operon from N. meningitidis. Further 
research indicated these genes were not present anywhere in the N. meningitidis genome 
(Hicks & Mullholland, 2018). This suggests N. meningitidis relies on L-cystine import 
and de novo cysteine biosynthesis to meet its L-cysteine demands, or otherwise, has an 
alternate transporter for L-cysteine (Hicks & Mullholland, 2018). This difference may be 
due to variance in cysteine/cystine availability in the host infection sites of 




Figure 1.4: Comparison of L-cysteine and L-cystine ABC transporters in N. gonorrhoeae and 
N. meningitidis. The complete cystine ABC transporter is present in both Neisseria species (top). The 
cysteine ABC transporter operon present in only N. gonorrhoeae (bottom). Directions of arrows indicate 
direction of transcription. Dashed lines represent areas of homology. Figure from (Hicks & Mullholland, 
2018). 
Importation of L-cysteine and L-cystine from the environment is well conserved across 
many species of bacteria, particularly in pathogens. This provides an advantage over de 
novo synthesis of L-cysteine, as importation is a less energy dependent process 
(Takahashi et al., 2018). However, transportation alone would not be ideal in an oxidative 
environment, such as the infection sites of both N. gonorrhoeae and N. meningitidis, or a 
cysteine/cystine deplete environment, therefore justifying the need for de novo 
biosynthesis of L-cysteine.    
1.5.4 Cysteine biosynthesis 
The cysteine biosynthesis pathway is a two-step reaction, catalysed by two enzymes, 
serine acetyltransferase (SAT) and O-acetylserine sulphydrylase (OASS), denoted as 
CysE and CysK/CysM (OASS isoforms), respectively. First, CysE catalyses the 
acetylation of L-serine, forming O-acetylserine and CoA (Figure 1.5). In the final step, 
O-acetylserine undergoes a CysK catalysed condensation reaction with sulphide to form 
L-cysteine (Figure 1.5). This two-step pathway is regulated at its first step by feedback 
inhibition with L-cysteine (Figure 1.5).  
 
Figure 1.5: Cysteine biosynthesis pathway. CysE denoted as SAT and CysK denoted as OASS. Red line 
indicates cysteine feedback inhibition of CysE. Figure adapted from (Yi et al., 2013) 
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CysE is a member of the left-handed parallel β-helix family that catalyse the committed 
step in the de novo synthesis of L-cysteine in both plants and bacteria (Johnson et al., 
2005). CysE has been identified as an essential gene in N. gonorrhoeae (Remmele et al., 
2014) and while it is non-essential in N. meningitidis, the cysE deletion strain has 
impaired growth in media (Capel et al., 2016). The cysteine feedback inhibition of CysE 
is well conserved across bacteria and is the primary method for prevention of high 
concentrations of L-cysteine, which are toxic to bacteria (Takumi & Nonaka, 2016; 
Benoni et al., 2017b).  
 
OASS belongs to the tryptophan synthase β superfamily and the β-family of pyridoxal 
5’-phopshate (PLP) dependent enzymes making it a PLP dependent enzyme (Mino & 
Ishikawa, 2003; Guédon & Martin-Verstraete, 2007; Takumi & Nonaka, 2016). PLP is 
utilised as a cofactor in the active site of the enzyme. OASS has two isoforms, OASS-A 
(CysK) and OASS-B (CysM) (Kredich, 2008). Most bacteria have both CysK (OASS-A) 
and CysM (OASS-B) isoforms for cysteine biosynthesis using sulphide or thiosulphate 
respectively. S. typhimurium is one such example, where both OASS isoforms are present, 
however, CysK (OASS-A) was shown to be expressed in excess of CysM (OASS-B) 
under aerobic conditions, and vice versa under anaerobic conditions (Tai et al., 1993). 
CysM differs from CysK, as it can directly utilise thiosulphate to produce 
S-sulphocysteine, which is then reduced to L-cysteine (Tai et al., 1993). Interestingly, 
Neisseria species are unique in that they only have one OASS isoform. This has greatest 
homology to CysK (OASS-A) and is hypothesise to utilise sulphide for cysteine 
biosynthesis (Hicks & Mullholland, 2018). This raises interesting questions regarding the 
role of CysK in N. gonorrhoeae, with the bacterium’s inability to reduce sulphate to 
sulphide and its reliance on thiosulphate for cysteine biosynthesis, a substrate that is 
usually utilised by the alternate OASS isoform CysM. While cysK is not an essential gene 
for pathogenic Neisseria species (Remmele et al., 2014), it has been shown to be 
important for colonisation of epithelial cells in N. meningitidis and when knocked out 
results in both decreased fitness and increased susceptibility to antibiotics (Turnbull & 
Surette, 2010; Capel et al., 2016).  
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1.6 Regulation of cysteine biosynthesis 
1.6.1 Transcriptional regulation of sulphate acquisition and cysteine 
biosynthesis 
Transcriptional regulation of the cysteine regulon is controlled by the master regulator 
CysB, a homotetramer, and a member of the LysR family of transcription factors 
(Jovanovic et al., 2003; Hicks & Mullholland, 2018). The CysB N-terminal domain 
contains a helix-turn-helix motif which allows DNA binding to occur (Lochowska et al., 
2004). The CysE product OAS is unstable and rapidly non-enzymatically forms the 
isoform N-acetylserine, both of which cause CysB to positively regulate the sulphate 
acquisition and cysteine biosynthesis genes, however, N-acetylserine produces a 
markedly higher response (Ostrowski & Kredich, 1989; Hryniewicz & Kredich, 1991).  
It is proposed that binding of N-acetylserine causes a conformational change in CysB, 
which then binds to CysB binding regions and recruits RNA polymerase (Hicks & 
Mullholland, 2018). CysB has been shown to upregulate expression of sulphate 
acquisition genes cysJIH, cysK, and cysP, alongside negatively autoregulating its own 
transcription through binding upstream of its own promoter (Ostrowski & Kredich, 1989, 
1991; Lochowska et al., 2004). The DNA binding repeat for CysB 
(CCGTTG-N17-CAACGG) was found in the cysB promoter region in both 
N. gonorrhoeae and N. meningitidis (Hicks & Mullholland, 2018). However, these 
binding sites could not be confirmed at the start of either the cysteine biosynthesis or the 
sulphate reduction regulon genes in N. gonorrhoeae. This could be a consequence of low 
conservation of the CysB binding sequences.  
 
Transcriptional regulation of both the cysteine regulon and the sulphate acquisition 
pathway are of particular importance to pathogenic bacteria, as successful infection 
depends on the ability of the pathogen to rapidly adapt and overcome host defences. 
Alongside this, cysB has been identified as an essential gene in N. gonorrhoeae (Remmele 
et al., 2014). CysB transcriptional regulation has control over many sulphate acquisition 
genes including that of cysK and thus, also has complete control over expression of the 




1.6.2 The cysteine synthase complex 
Feedback inhibition of CysE is not the only method through which sulphur flux 
throughout the cysteine biosynthesis pathway is regulated. The other mechanism for 
regulating sulphur flux in this pathway is the formation of the cysteine synthase complex 
(CSC). The complex is composed of the two enzymes that catalyse the two step cysteine 
biosynthesis pathway, CysE and CysK. Gel filtration chromatography and fluorescence 
studies have shown that this complex consists of a 3:2 protomer ratio, consisting of one 
CysE hexamer and two CysK dimers (Figure 1.6) (Kredich et al., 1969; Johnson et al., 
2005; Benoni et al., 2017b; Hicks & Mullholland, 2018).  
 
Figure 1.6: Analysis of the cysteine synthase complex from E. coli. (a) Gel filtration chromatograph of 
CSC, CysE and CysK. (b) Formation of the CSC through monitoring PLP emission at 500 nm with 
increasing [CysE:CysK] molar ratio. Figure adapted from (Benoni et al., 2017b). 
This complex was first discovered during the purification of CysK and CysE from 
S. typhimurium (Kredich & Tomkins, 1966; Kredich et al., 1969). Further evidence of 
CSC formation has been found in other bacterial species, including E. coli (Mino et al., 
2000; Benoni et al., 2017b), Haemophilus influenzae (Huang et al., 2005), and 
M. tuberculosis (Schnell et al., 2007), as well as some plant species (Yi et al., 2013). In 
this formation, the C-terminal tail of CysE inserts into the active site of CysK to inhibit 
its activity.  
 
Formation of the CSC is essentially controlled by sulphur availability. When the complex 
is formed, CysE loses sensitivity to feedback inhibition by L-cysteine, and catalytic 
activity increases as a result of reduced substrate inhibition by L-serine (Benoni et al., 
2017b). With high availability of sulphur to the cell, the CSC is stabilised by bisulphide, 
conversely, when sulphur availability is low, O-acetylserine (OAS) accumulates, 




et al., 2017b). Dissociation of the CSC can occur at µM OAS concentrations (upwards of 
50µM OAS) (Kredich et al., 1969; Wang & Leyh, 2012), OAS is then able to non-
enzymatically isomerise to N-acetylserine, which can bind to transcriptional regulator 
CysB, promoting expression of sulphate acquisition genes (Jovanovic et al., 2003; 
Kredich, 2008; Wang & Leyh, 2012). In contrast to the CSC formations effect on CysE, 
CysK becomes almost completely inhibited (Saito et al., 1995). 
 
Binding of the CysE C-terminal peptide into CysK’s active site has been confirmed 
through fluorescent spectroscopy peptide binding studies, where a blue shift in emission 
(500 nm) is observed by PLP, the co-factor of CysK (Campanini et al., 2014). The CSC 
is an important regulator of the cysteine biosynthesis pathway and has yet to be 
characterised in N. gonorrhoeae.  
 
The CSC structure has not yet been established, however, there is a crystal structure of 
CysK from H. influenzae, with a 10 amino acid C-terminal peptide bound in the active 
site (Huang et al., 2005). The key residues required for binding were determined via 
screening a tetrapeptide library. Binding ability was monitored by CysK activity and PLP 
fluorescence (Campanini et al., 2014). It was determined that a C-terminal isoleucine (Ile) 
is essential for binding and inhibition of CysK.  This residue is well conserved across 
CSC forming organisms, including S. typhimurium, H. influenzae and E. coli (Huang et 
al., 2005; Salsi et al., 2011; Benoni et al., 2017b).  
 
Previous research using Clustal Omega (Madeira et al., 2019), generated a sequence 
alignment of CysE bacterial homologues that was analysed using ESPript 3.0 (Robert & 
Gouet, 2014). This analysis concluded that CysE from N. gonorrhoeae had moderate 
sequence similarities to other CysE homologues (57%, however, with a 97% similarity to 
N. meningitidis being the exception) (Oldham, 2020). The C-terminus four peptide 
fragment, GDGI was well conserved across three species with DFMI being the conserved 
peptide sequence in Neisseria species (Oldham, 2020). The conservation of this terminal 
Ile indicates potential formation of the CSC in N. gonorrhoeae. It has also been confirmed 
that the CysK active site serves as the anchor for the formation of the CSC (Campanini et 
al., 2015). Given the complete inhibition of CysK by the CSC formation and key 
differences in sulphur acquisition and cysteine biosynthesis shown in other bacterial 
species, characterisation both CysK and the CSC in N. gonorrhoeae would provide 
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further insight into elucidating the sulphur assimilation and synthesis of L-cysteine in 
N. gonorrhoeae.  
1.7 O-acetylserine sulphydrylase/CysK 
1.7.1 Structural characteristics of CysK 
O-acetylserine sulphydrylase (OASS), CysK, is a pyridoxal 5’phosphate (PLP) dependent 
enzyme belonging to the OASS belongs to the tryptophan synthase β superfamily (Fold 
type II) (Takumi & Nonaka, 2016). Characteristic of this, the lysine (Lys) residue key to 
forming a Schiff base with the aldehyde group of PLP is located closer to the N-terminus 
of each monomer, while the loop region that binds to the phosphate group of PLP is closer 
to the C-terminus of each monomer (Liang et al., 2019). Another important distinction, 
the active site of the enzyme is made up of residues all from one subunit, compared to the 
fold type I family where the active site is made of residues combined from different 
subunits (Liang et al., 2019). CysK is a homodimer comprised of two subunits, each of 
approximately 315 amino acid residues, composed of two domains, an N-terminal domain 
(formed predominantly by residues 1-145) and a C-terminal domain (formed 
predominantly by residues 146-315) (Rabeh & Cook, 2004). Each domain consists of an 
α/β fold with a central twisted β-sheet surrounded by α-helices  
Figure 1.7) (Rabeh & Cook, 2004). Crossover of N-terminus residues (13-34) into the 
C-terminal domain form the first two strands of these central β-sheets (Rabeh & Cook, 
2004).  The active site of each subunit is located deep within the protein at the interface 
of the N-terminal and C-terminal domains. 
 
 
Figure 1.7: Cartoon representation of the S. typhimurium CysK structure (PDB # 2J3C). (a) Structure of 
the CysK dimer, with monomers coloured purple and green respectively. Bound PLP shown in licorice-
stick format in green and orange respectively. (b) Structure of the CysK monomer, coloured from N-
terminus (blue) to C-terminus (red). The central twisted β-sheet is surrounded by α-helices in both domains. 




Combination of improved stability and an allosteric anion-binding site at the dimer 
interface give purpose to the formation of the dimeric structure CysK forms (Rabeh & 
Cook, 2004).  
 
To date there are 34 bacterial CysK structures deposited in the Protein Data Bank (PDB). 
Both structural and functional conservation of CysK is found across gram-negative 
bacteria and plant species, independent of sequence similarities (Benoni et al., 2017a). 
Within the active site, the PLP cofactor is in Schiff base linkage with the amino group of 
Lys-41 (Figure 1.8), whilst its pyridine ring is supported at the back by Valine (Val)-40. 
Main and side chain functional groups within the Glycine (Gly)-176-Threonine (Thr)-
180 loop, anchor the 5’-phosphate of PLP (Figure 1.8) (Rabeh & Cook, 2004). The amide 
nitrogen and Schiff base nitrogen of the Asparagine (Asn)-71 residue can hydrogen bond 
with the O-3’ of PLP. The asparagine loop alongside Glutamine (Gln)-142 bind the 
substrate carboxylate group in the external Schiff base (Rabeh & Cook, 2004). Serine 




Figure 1.8: Active site residues of CysK. (a) Threonine loop (T177-T180) which interacts with 5’-
phosphate of PLP seen on the left. (b) Asparagine loop (residues 68-72) seen on the right. Cofactor PLP is 
visible at the bottom of the active site cleft. Schiff base linkage between C-4’ of PLP and Lys-41 can be 
seen. Ser-272 is within hydrogen bonding distance of N-1 of the pyridine ring in PLP. Side chain of 
Asparagine (Asn)-71 interacts with O-3’ of PLP. Figure taken from (Rabeh & Cook, 2004). 
Consensus sequence analysis of CysK enzymes has indicated 5’-phosphate PLP 
anchoring by a Gly-Thr loop (GTGGT) is conserved across 10 bacterial species ranging 
from residues 166-170 to residues 191-195 (Joshi et al., 2019). The exact same GTGGT 
motif is found in the N. gonorrhoeae CysK sequence at residues Gly-179-Thr-183 (Figure 
3.13). The Schiff base linkage forming Lys-41 found in S. typhimurium is also conserved 
across 11 bacterial species ranging from residue position 35-58. This lysine is analogous 
to Lys-44 in N. gonorrhoeae. The asparagine that hydrogen bonds to O-3’ of PLP, and 




are also conserved across 11 bacterial species and are found in N. gonorrhoeae at residues 
Asn-74 and Gln-145, respectively. Ser-272 which hydrogen bonds with PLP’s pyridine 
nitrogen is also conserved across these 11 bacterial species and is found in 
N. gonorrhoeae at Ser-267. The active site residues Thr69-Thr73 and Gly228-Ala231 are 
conserved across nine bacterial species and are found in N. gonorrhoeae at Thr71-Thr75 
and Gly223-Ala226, respectively. The presence of these similarly positioned and 
conserved residues involved in the active site and cofactor binding in CysK indicates 
similar structure and function of the previously uncharacterised N. gonorrhoeae CysK 
enzyme to other CysK enzymes found in literature.  
 
However, structural characteristics will only partially elucidate N. gonorrhoeae CysK’s 
function and role in the sulphur acquisition and cysteine biosynthesis pathways.  The 
kinetic mechanism will help further characterise the function of N. gonorrhoeae CysK. 
1.7.2 CysK kinetic mechanism 
The kinetics of CysK homologues have been studied extensively in both bacteria and 
plant species. As CysK uses two substrates in its reaction to produce L-cysteine, there are 
two possible catalytic mechanisms for its action: sequential and ping-pong. Many studies 
in literature have already determined the CysK reaction mechanism to be bi-bi ping-pong 
(also known as a non-sequential mechanism) (Rabeh & Cook, 2004; Joshi et al., 2019). 
The ping-pong mechanism involves release of one of the products before all substrates 
have bound to the enzyme, generating an enzyme intermediate in the process (Ulusu, 
2015). The bi-bi ping-pong mechanism utilised by CysK begins with diffusion of OAS 
into the active site, and an elimination reaction occurs, removing acetate, forming the 
intermediate α-aminoacrylate. Nucleophilic attack of sulphide results in formation of 




Figure 1.9: Mycobacterium tuberculosis CysK catalytic mechanism. Figure from (Joshi et al., 2019). 
This mechanism has been identified in CysK from both S. typhimurium and 
M. tuberculosis (Rabeh & Cook, 2004; Joshi et al., 2019), indicating N. gonorrhoeae may 
utilise the same mechanism of cysteine production.  
1.8 CysK as a drug target 
Given the importance of the cysteine biosynthesis pathway in pathogen virulence and 
overcoming oxidative stress, targeting this pathway has become of particular interest in 
development of new antimicrobials. Mammals synthesise L-cysteine through reverse-
transulphurisation of methionine obtained in the diet, thus, the lack of cysteine 
biosynthesis and a reductive sulphate acquisition pathway, makes this pathway a 
particularly promising target for drug development (Stipanuk et al., 2006; Hicks & 
Mullholland, 2018). Development of inhibitors for targeting CysK isoforms in pathogenic 
bacteria, including S. typhimurium (Spyrakis et al., 2013), H. influenzae (Salsi et al., 2010) 
and M. tuberculosis (Jean Kumar et al., 2013) has already begun.   
 
A transcriptomic study showed that cysK is not an essential gene for N. gonorrhoeae 
(Remmele et al., 2014). This transposon-mediated mutagenesis study was conducted in 
the presence of cysteine, and under these conditions the first enzyme (CysE) in the 
two-step cysteine biosynthesis pathway was essential, yet curiously the second enzyme 
(CysK) was not. This demonstrates that L-cysteine requirements for N. gonorrhoeae 
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cannot be met solely from environmental import of L-cysteine, and is supported by 
N. gonorrhoeae being able to grow in the absence of cysteine and the presence of 
thiosulphate (Le Faou, 1984). However, CysK is important for colonisation of epithelial 
cells in N. meningitidis and when deleted results in both decreased fitness and increased 
susceptibility to antibiotics (Turnbull & Surette, 2010; Capel et al., 2016).   
 
Although CysK has been evaluated as a drug target in S. typhimurium, H. influenzae, and 
M. tuberculosis, cysteine biosynthesis has not been investigated in N. gonorrhoeae. 
N. gonorrhoeae lacks the necessary transporters for glutathione uptake and therefore, 
relies on the precursor cysteine for synthesis of glutathione (Seib et al., 2006). Although 
N. gonorrhoeae has cysteine and cystine transporters, it is likely N. gonorrhoeae relies 
on de novo cysteine biosynthesis to maintain high intracellular glutathione concentrations 
given the essential nature of both cysB and cysE. Given CysK is the final step in the de 
novo biosynthesis of L-cysteine, this places high importance on elucidating its function 
in the pathogenicity of N. gonorrhoeae.  
 
Although N. gonorrhoeae cannot grow on sulphate as its lacks the enzyme required for 
reducing sulphate to sulphide (due to genome deletions and in frame stop codons), it is 
able to grow on thiosulphate as the sole source of sulphur. We suggest that 
N. gonorrhoeae has a different, yet functional cysteine biosynthesis pathway from other 
Neisseria species, and as a function of that pathway, a dual-functioning CysK which 
utilises both thiosulphate and sulphide for the final step in the synthesis of cysteine. 
Genome searches and sequence comparisons identified and annotated a likely functional 











1.9 Research objectives 
 The aim of this research is to characterise a key enzyme in the N. gonorrhoeae cysteine 
biosynthesis pathway, O-acetylserine sulphydrylase/CysK. Characterisation of the 
biochemical and biophysical properties of CysK from N. gonorrhoeae will guide future 
research into the development of new antimicrobials and will improve our understanding 
of the pathogenicity of N. gonorrhoeae. The following objectives were set to achieve this: 
 
Objective 1: 
Investigate the O-acetylserine sulphydrylase activity and peptide inhibition of CysK from 
N. gonorrhoeae.  
 
Objective 2: 
Determine the three-dimensional structure of CysK using protein crystallisation and 
X-ray diffraction.  
 
Objective 3: 
Characterise the cysteine synthase complex of N. gonorrhoeae.  
 
Objective 4: 
Create genetic knockouts of the cysK gene from N. gonorrhoeae to test the essentiality of 






Materials and Methods 
2.1 Cloning of cysK for expression in Escherichia coli 
The cysK gene NGO_0340 was codon optimised for E. coli and ordered from Geneart 
(Thermo Fisher) (Appendix A.1). The synthetic cysK construct was cloned into 
expression vector pET28b-PstI with a C-terminal hexahistidine-tag, between PstI and 
XhoI restriction sites by Dr Joanna Hicks (The University of Waikato). The NGO_0340 
pET28b plasmid was checked by DNA sequencing before transformation into E. coli 
BL21 (DE3) for protein expression. Positive transformants were selected for by growing 
overnight at 37°C, Luria-Bertani (LB) agar (Appendix A.2) supplemented 
with 50 µg.ml-1 kanamycin 
2.2 Long term storage of BL21 CysK expression strains 
Seeder cultures were prepared from positive transformants, by inoculating a single colony 
from a transformation plate into LB broth (10 ml) supplemented with kanamycin 
(50 µg.ml-1) and incubated at 37 °C, shaking at 200 rpm, overnight. Glycerol stocks were 
prepared from seeder cultures, by adding 0.5 ml of seeder culture to 0.5 ml sterile 50% 
glycerol (w/v) and stored at -80 °C. 
2.3 CysK expression cultures 
Large scale expression cultures were prepared by inoculating the 10 ml seeder culture 
(prepared as per section 2.2) into 1 L LB broth, supplemented with kanamycin 
(50 µg.ml-1). Cultures were incubated at 37 °C, 200 rpm until the culture reached mid-log 
phase (optical density at A600 = 0.5-0.7), at which point protein expression was induced 
by the addition of 1 ml of 0.75 M isopropylthio-β D-galactosidase (IPTG, final 
concentration 0.75 mM). Cultures were incubated overnight at 22 °C, 200 rpm. 
Expression cultures were centrifuged at 4,600 g for 20 min at 4 °C, after which the 
supernatant was discarded. The remaining cell pellet was resuspended in 15 ml lysis 
buffer (50 mM potassium phosphate pH 7.0, 200 mM NaCl, 20 mM imidazole). The 
resuspended culture was transferred to a 50 ml falcon tube and centrifuged for a further 
20 min at 4,600 g, 4 °C. After centrifugation, the supernatant was discarded, and the pellet 
was stored at -80°C. 
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2.4 Purification of CysK 
CysK was isolated and purified using immobilised metal affinity chromatography (IMAC) 
and gel filtration chromatography. Protein solubility was assessed using SDS-PAGE gel 
electrophoresis. Oligomeric state was measured using gel filtration chromatography and 
native-PAGE gel electrophoresis. 
2.4.1 Immobilised metal affinity chromatography 
Frozen CysK cell pellets (section 2.3) were thawed at room temperature. Cell pellets were 
resuspended by vortexing in 12.5 ml lysis buffer (50 mM Potassium phosphate pH 7.0, 
200 mM NaCl, 20 mM imidazole), 625 µL of 2mM PLP was added (for final 
concentration of 0.1 mM) and one cOmpleteTM, Mini, EDTA-free Protease Inhibitor 
Cocktail tablet (Roche, Switzerland) was added to inhibit cellular proteases. Cells were 
lysed on ice using a QSONICA Q700 sonicator using programme 2 with a 1/4” microtip 
probe (12.5-25 ml volume). Programme 2 involves alternating 2 second bursts at 12% 
power with 2 second intervals of no sonication for a total of 1.5 min. The sonicated lysate 
was centrifuged at 13 000 g for 20 min at 4 ºC. The supernatant was filtered through 1.2, 
0.45 and 0.2 µm filters. IMAC purification was carried out using either an AKTÄ Purifier 
fast protein liquid chromatography (FPLC) system (GE Life Sciences) or an NGC FPLC 
system (BioRad). The same method for IMAC and gel filtration was used for either FPLC 
system. The filtered supernatant was manually loaded onto a HisTrapTM HP 5 ml column 
(GE Life Sciences) that was preequilibrated in lysis buffer. The column was attached to 
the FPLC and washed with 20 ml lysis buffer at 2 ml.min-1 to remove unbound proteins. 
A gradient of elution buffer (50 mM potassium phosphate pH 7.0, 200 mM NaCl, 1 M 
imidazole) was gradually increased to 50%, over 25 ml, to elute the HexaHis-tagged 
CysK. 
2.4.2 Gel filtration chromatography 
At room temperature (22 °C), 1 ml of a single IMAC peak fraction containing CysK was 
loaded onto an Enrich 650 analytical gel filtration column (Bio-Rad Laboratories, USA), 
preequilibrated in gel filtration buffer (50 mM Potassium phopshate pH 7.0, 100 mM 
NaCl) with a flow rate of 1 ml.min-1. An IMAC protein fraction was manually loaded into 
the injection loop of the FPLC for injection onto the column. After sample injection, 
28 ml gel filtration buffer was run at 1 ml.min-1 through the column. Fractions of eluted 
protein were collected, nanodropped and diluted with gel filtration buffer to 1.6 mg.ml-1 
in 1 ml. 50% glycerol (1 ml) was added to diluted protein (2 ml, final concentration of 
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0.8 mg.ml-1 CysK) and stored at -80 ºC. These CysK stocks (2ml, 0.8 mg.ml-1) were later 
thawed and 80 µL aliquoted into 1.5 ml tubes and stored at -80 ºC.  
2.4.3 SDS-PAGE gel electrophoresis 
SDS-PAGE gels were composed of both a resolving and stacking layer, at 12 and 5% 
polyacrylamide, respectively. All gels were made in house in a multi-gel caster (Hoefer). 
The resolving layer was prepared by mixing the “Resolving layer” components listed in 
Table 2.1, and filling the gel caster, leaving a three cm gap at top of the gel plate. A thin 
layer of isopropanol was then applied to the top of the gel and was left until the resolving 
layer had polymerised ~30 min. Once set, the isopropanol layer was carefully removed, 
the stacking layer was prepared by combining “Stacking Layer” components listed in 
Table 2.1 and filling to the top edge of the gel caster. A ten well comb was inserted into 
the top of each gel, before leaving to set at room temperature ~30 min. Gels were stored 
wrapped in wet tissue at 4 °C for up to four weeks. Protein samples were prepared for 
gel-loading by mixing 15 µL sample with 5 µL 4x SDS loading dye (also known as 
Quench, Q4) (Appendix B.3). 20 µl of sample was loaded per well, along with 10 µl of 
Precision Plus ProteinTM ladder (Bio-Rad Laboratories, USA) per gel. The gels were run 
in 1 x Tris-Glycine SDS-PAGE running buffer (Appendix B.3) at 100 V, until the loading 
dye migrated past the stacking gel where it was increased to 150 V. The gel was stopped 
when the dye migrated to the end of the resolving gel. Protein bands were visualised by 
staining in Coomassie Fairbanks stain (Appendix B). Gels and stain were heating by 
microwaving for 30 s, followed by five min incubation at room temperature with agitation. 
Stained gels were rinsed with distilled water and left in destaining solution (10% acetic 
acid) overnight. Destained gel bands were visualised using an Omega Lum™ gel imager 













Table 2.1: Components for five SDS-PAGE gels. Ammonium persulphate (APS2) stock solution was 
prepared fresh weekly. 
Component 12% Resolving layer 
(ml) 
8% Stacking layer (ml) 
Resolving buffer (1.5 
M Tris pH 8.8) 
7.5 - 
Stacking buffer (1 M 






10% SDS (w/v) 0.30 0.125 
10% APS2 (w/v) 0.15 0.063 
10% TEMED 0.015 0.0063 
MQ H2O 10.05 8.50 
 
2.4.4 Measuring the oligomeric state of CysK 
Previously, the Enrich650 gel filtration column (Bio-Rad Laboratories, USA) was 
calibrated in gel filtration buffer (50 mM Tris pH 8.0, 200 mM NaCl) using Gel Filtration 
Standards (Bio-Rad Laboratories, USA), by Dr Joanna Hicks (Appendix B).  The 
molecular weight of CysK was calculated taking the peak elution volume (Ve) and 
calculate the Kav gel phase distribution co-efficient using Equation 2.1, where Vo is the 
column void volume and Vc is the total column volume: The calibration standard curve 
relating Kav and molecular weight was used to determine the molecular weight of CysK 
from the calculated Kav. 
 












2.4.5 Measuring protein concentration NanodropTM 
Protein concentration was determined by NanodropTM 2000 (Thermofisher, USA) 
measuring absorbance at 280 nm. Protein concentration was calculated using Beer-
Lambert law (Equation 2.2), where absorbance readings were corrected by dividing the 
NanodropTM reading (1 Abs = 1 mg.ml-1) by the molar absorption co-efficient of the CysK 
protein, (Ɛ = 0.590 L mol-1/cm-1) as determined by ProtParam (Gasteiger et al., 2005). 
 
Equation 2.2: Beer-Lambert equation. A= absorbance, Ɛ = molar absorption co-efficient (L mol-1 /cm-1), 
l = pathlength (cm) and c = concentration (molL-1). 
𝐴 = 𝜀𝑐𝑙 
 
2.5 Kinetic Assay Parameters 
CysK was purified by IMAC and gel filtration chromatography as per sections 2.4.1 and 
2.4.2. Protein concentration was measured by absorbance at 280 nm using a NanodropTM 
(section 2.4.5). CysK protein used in the first assay sets was purified the same day. After 
glycerol stabilisation and freezer storage, all CysK enzyme used in subsequent assays was 
from the 0.8 µg freezer stocks stored at -80 ºC. All assays were carried out in MOPs buffer 
(100mM MOPs). Substrates O-acetylserine (OAS) and sodium sulphide (Na2S) were 
freshly prepared for each set of assays (Appendix B3).  Enzyme stocks (80 µL of 0.8 
mg.ml-1, 0.02 nM, CysK monomer 32.726 kDa) from the freezer were thawed at room 
temperature ~2 mins before assays were begun.  
2.5.1 Assay parameters 
Assay data was collected using MOPs buffer (100mM MOPs). Assays were carried out 













Table 2.2: CysK activity assays with varying O-acetylserine concentrations. Concentrations of substrate 
were varied by adjusting the volume of substrate 50 mM stock added, unless the volume to be added was 
less than 3 µl, then a 5 mM stock was used. This was done to prevent inaccuracy of pipetting at extremely 
low volumes. The amount of enzyme used for each reaction was kept constant (1.6 mg.ml-1).  
Component Volume (µL) 
O-acetylserine (5/50mM, substrate) 3-30 
Sodium sulphide (50mM, substrate) 10.5 
MOPs (100mM, initial reaction) 32.5-62.5 
CysK (0.8 mg.ml-1, Enzyme) 2 
TCA (20%) 15 
DTT (200mM) 16.5 
MOPs (100mM, reduction step) 3.5 
Acid Ninhydrin 100 
Glacial Acetic acid 100 
Total (95 ºC incubation step) 310 
Ethanol (Ice cold, 100%) 100 
Reaction mixture 100 
Total (measuring step) 200 
 
Table 2.3: CysK activity assays with varying sodium sulphide concentrations. Concentrations of substrate 
were varied by adjusting the volume of substrate 50 mM stock added, unless the volume to be added was 
less than 3 µl, then a 5 mM stock was used. This was done to prevent inaccuracy of pipetting at extremely 
low volumes. The amount of enzyme used for each reaction was kept constant (1.6 mg.ml-1).  
Component Volume (µL) 
O-acetylserine (50mM, substrate) 15 
Sodium sulphide (5/50mM, substrate) 3-45 
MOPs (100mM, initial reaction) 13-58 
CysK (0.8 mg.ml-1, Enzyme) 2 
TCA (20%) 15 
DTT (200mM) 16.5 
MOPs (100mM, reduction step) 3.5 
Acid Ninhydrin 100 
Glacial Acetic acid 100 
Total (95 ºC incubation step) 310 
Ethanol (100%, Ice cold) 100 
Reaction mixture 100 




All substrate stocks were prepared in MQ H2O. All components for the assays, except 
MOPs, acetic acid, ethanol and the enzyme were made fresh just before assays were 
conducted. OAS stocks were made fresh due to the rapid conversion of O-acetylserine to 
N-acetylserine (Campanini et al., 2005). O-acetylserine was purchased as a powder from 
Sigma Aldrich (MW = 183.59 g.mol-1) and stored as a powder at -20 ºC according to 
manufacturer’s instructions. Sodium sulphide stocks were made fresh to prevent any 
possible error in activity that could be caused by substrate degradation. Sodium sulphide 
was purchased as a fragmented solid from Sigma Aldrich (MW = 142.02 g.mol-1) and 
stored at 4 ºC according to manufacturer’s instructions. DTT was made fresh as it has a 
very short half-life (Stevens et al., 1983). DTT was purchased as a fragmented solid from 
Sigma Aldrich (MW = 154.253 g.mol-1) and stored at 4 ºC according to manufacturer’s 
instructions. TCA was made fresh to prevent any possible error in activity that could be 
caused by degradation of TCA. TCA was purchased as a clear crystalline solid from 
Sigma Aldrich (MW = 163.38 g.mol-1) and stored at 4 ºC according to manufacturer’s 
instructions.  
 
O-acetylserine sulphydrylase activity of CysK was monitored via absorbance 
measurements of L-cysteine at 560 nm using an adapted method from (Gaitonde, 1967). 
Absorbance at 560nm was recorded across five stopped assay time points (0, 2.5, 5, 7.5 
and 10 mins) using a Thermo Scientific Multiskan GO spectrophotometer 
(ThermoScientific, USA). Absorbance readings were subsequently corrected for by 
subtracting any absorbance from blank samples and converted to cysteine produced (mM) 
using the cysteine standard curve determined during a summer research project 
(Appendix B.2). Cysteine produced for each varied substrate concentration condition was 
plotted and the catalytic rates (cysteine produced mM.min-1) for each were derived from 
linear regression analysis of the first five minutes of the stopped assay reactions (unless 
otherwise stated).  
 
OAS, sodium sulphide and MOPs were added in appropriate volumes for each reaction 
condition to individual wells in the 96-well plate. The enzyme was added directly to the 
side of the wells. Finally, the reaction was initiated via 30 second centrifugation at 3000 
rpm, 4 ºC (Heraeus Multifuge 3SR Plus centrifuge). The 96-well plate was covered 
(Platemax CyclerSeal Sealing Film, PCR-TS) and incubated for 10 mins at 37 ºC. Each 
reaction was stopped by addition of 15 µl TCA (w/v) at 0, 2.5, 5, 7.5 and 10 minutes 
accordingly. 16.5 µL of 200mM DTT (final concentration 30 mM) and 3.5 µL of 100mM 
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MOPs were added to each well and incubated at room temperature for 30 mins. 100 µL 
of acid ninhydrin and 100 µL of acetic acid were added to each well and incubated for 5 
mins, at 95 ºC. The plate was cooled by incubating on ice for 5 mins, and 100 µL ice cold 
ethanol and 100 µL of each reaction mixture were added to a flat bottomed 96-well plate. 
Absorbance was measured at 560nm (Thermo scientific, Multiskan GO). Enzyme rates 
were plotted using GraphPad Prism (version 8.2.0, Windows, GraphPad Software, La 
Jolla California USA). All datapoints were collected in duplicate, unless otherwise stated.  
2.6 Kinetic analysis 
The KM and Vmax were calculated for each substrate by varying the concentration of the 
substrate of interest, while keeping the other substrate at a saturating concentration, so it 
is not rate limiting. Saturating conditions are defined as concentrations 2 x KM, and greater. 
O-acetyl-L-serine Michaelis Menten curves were collected over a range of 
O-acetyl-L-serine concentrations (0.2-10 mM). Sodium sulphide Michaelis Menten plots 
were collected over a range of sodium sulphide concentrations (0.2-12 mM). Both 
Michaelis Menten plots were collected at fixed saturating conditions (10mM OAS and 
7mM Na2S) of the other substrate.  
 
KM and Vmax were determined by non-linear regression fit of the Michaelis Menten 
equation (Equation 2.3), the allosteric sigmoidal equation (Equation 2.4), the substrate 
inhibition equation (Equation 2.5) or the allosteric sigmoidal with substrate inhibition 
equation (Equation 2.6) (using GraphPad Prism (version 8.2.0, Windows, GraphPad 
Software, La Jolla California USA,). 
Equation 2.3: The Michaelis Menten equation. S = substrate, KM = Michaelis constant, v = rate, 





Equation 2.4: The allosteric sigmoidal equation. S = substrate, Khalf = Michaelis constant, v = rate, 
vmax = theoretical maximum rate, h = hill constant. 






Equation 2.5: The substrate inhibition equation. S = substrate, KM = Michaelis constant, v = rate, 
vmax = theoretical maximum rate, Ki = dissociation constant for substrate binding in a situation where two 












Equation 2.6: The allosteric sigmoidal with substrate inhibition equation. S = substrate, KM = Michaelis 
constant, v = rate, vmax = theoretical maximum rate, h = hill constant, Ki = dissociation constant for substrate 












Enzyme catalytic efficiency was determined by calculating the catalytic constant (kcat) 
and the specificity constant kcat/KM. kcat is a measure of the amount of product formed 
over time, per unit of enzyme (s-1). This is calculated by dividing the Vmax rate (M.s
-1) by 
the molar concentration of dimeric enzyme. The catalytic efficiency kcat/KM (M
-1s-1) was 
calculated by dividing the kcat (s
-1) by the KM (M). Catalytic efficiency values were 
calculated for each substrate. 
2.7 Thiosulphate substrate assays  
Thiosulphate substrate assays were conducted using a modified method from section 
2.5.1. The key modification was substitution of thiosulphate for sodium sulphide in the 
reaction. Thiosulphate was added at low to high varied concentrations (final reaction 
concentration, 1-50 mM).  
2.8 CysK inhibition assays 
The CysE C-terminal tetrapeptide (DFMI) was ordered from Thermo scientific 
(MW = 523.54 g.mol-1) as a white powder and stored at 4 ºC according to manufacturer’s 
instructions.  CysE tetrapeptide was suspended in 1 ml of potassium phosphate gel 
filtration buffer (Appendix B.1) to a stock of 2 mg.ml-1 (3820.15 pmol), which was further 
diluted to stocks of 0.2, 0.02 and 0.002 mg.ml-1 (382, 38.2 and 3.82 pmol respectively) 
and stored at -21 ºC (Appendix B.4).  
 
CysE C-terminus tail four peptide inhibitor assays were measured using a modified 
method from section 2.5.1. Modifications included the addition of the CysE C-terminus 
tail four peptide inhibitor (total inhibitor added, 0.08-191 pmol); using thawed 2 mg.ml-1 
stock or diluted stocks if volume added dropped below 2µL; to appropriate volumes of 
thawed CysK for pre-incubation of the enzyme with the peptide. OAS concentration was 
held at 1 mM instead of 10 mM as OAS is known to cause dissociation of the cysteine 
synthase complex at very low concentrations. The reaction was initiated via addition of 
the pre-incubated stock and centrifugation.  
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2.9 Crystallisation of CysK 
2.9.1 Protein purification 
CysK protein was expressed and purified following methods in sections 2.3 and 2.4 
respectively using crystallisation buffers in Appendix B.2. Protein concentration was 
determined by NanodropTM as per section 2.4.5. 
2.9.2 High throughput crystallisation screens 
High throughput crystallisation screens were set up by Annmaree Warrender to identify 
promising crystallisation conditions that could be further optimised to produce crystals 
suitable for X-ray diffraction. The following screens: IndexTM-HR2-144, 
PEGRxHTTM-HR2-086, CrystalHTTM-HR2-130 and the SaltRxHTTM-HR2-136 
(Hampton Research, U.S.A.), were used. Screens were set up in low profile 96-2 well 
INTELLI-PLATE and were set up using the Mosquito crystallisation robot (TTP 
LabTech Ltd., USA). Each crystallisation condition had a reservoir solution 
(crystallisation solution) of 100 µl and 200 nl sitting drops of a 1:1 ration of protein (40 
mg.ml-1) and crystallisation solution. Screens were checked weekly for crystal formation 
using a dissection microscope (Nikon SMZ800). 
2.9.3 Hanging drop fine screens 
Purified protein was concentrated to 40 mg.ml-1 and stored on ice for a short period of 
time, as prolonged incubation at room temperature led to precipitation. Promising 
crystallisation conditions from high throughput screens were further optimised by 
Annmaree Warrender through scaling up to hanging drop fine screens. 24 well VDX trays 
were set up with crystallisation solution volumes of 500 µl or 1000 µl from concentrated 
stock solutions. Hanging drops were prepared by mixing a 1:1 ratio (1:1 µl or 2:2 µl) of 
mother liquor and concentrated protein solution on a siliconised cover slip, before 
inverting drop-side down, over a well, lined with silicone grease. For each condition, 
crystallisation parameters such as pH, drop size and the concentration of protein and 
precipitant were optimised. Crystallisation drops were checked for crystal growth under 
a dissection microscope, daily for one week and weekly thereafter.  
 
The fine screen that reproduced crystals from the robot screen was based on a condition 
from the CrystalHTTM robot screen (HR2-130, Hampton Research): 0.1 M HEPES 
sodium, pH 7.5, 2% polyethylene glycol 400 (v/v), 2.0 M Ammonium sulphate. Trays 
were set up as above. The hanging-drop the crystal looped from was from condition 0.1 
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M HEPES pH 7.5, 4% polyethylene glycol 400 (v/v), 2.5 M ammonium sulphate. Drop 
composition was 1:1 (mother liquor: protein concentrate) in a final volume of 2 µl. All 
crystals were grown at 18 °C. 
2.9.4 Crystal preparation for X-ray diffraction 
Each crystal was transferred using a cryo-loop, to a cryo-protectant solution, consisting 
of the crystallisation solution with the addition of 15% glycerol (v/v) as a cryo-protectant. 
Crystals were then flash cooled in liquid nitrogen. Crystals were stored short-term in 
liquid nitrogen (one to two days) before data collection. 
2.10 Data collection  
X-ray diffraction data was collected at the Australian Synchrotron (Melbourne, Victoria) 
on the MX2 beamline (McPhillips et al., 2002), equipped with an EIGER x 16M detector 
(Dectris, Switzerland). Data were collected over 360 ° rotation of the crystal over 360 sec, 
at 80% beam attenuation.  
2.11 Data processing  
2.11.1 Indexing, integration and scaling  
The CysK diffraction images were indexed, integrated and scaled, using XDS (Kabsch, 
2010). Datasets 0016 and 0017 were the best of three datasets obtained from the crystal 
diffraction. Unit cell dimensions of 0017 were changed to match 0016 and the space group 
changed from sg 19 (P212121) to sg 4 (P21) via rerun of XDS (Kabsch, 2010). The Original 
space group was found to be incorrect as the resulting model had unexpectedly high Rwork 
and Rfree values.  Datasets 0016 and 0017 were scaled together using XDS (Kabsch, 2010) 
and reflections merged using AIMLESS (Evans & Murshudov, 2013) from the CCP4 
suite (Winn et al., 2011). Data quality was assessed through AIMLESS (Evans & 
Murshudov, 2013). FreeR flag dataset (5% of dataset reflections not to be used in 
refinement and used to compute Rfree) was generated in AIMLESS.  
2.11.2 Detection of twinning and non-crystallographic symmetry 
Data was analysed for evidence of twinning and translational non-crystallographic 
symmetry (tNCS) in AIMLESS from the CCP4 suite (Winn et al., 2011; Evans & 
Murshudov, 2013) and phenix.xtriage from the PHENIX suite. 
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2.12 Structural analysis  
2.12.1 Matthew’s coefficient  
The total number of monomers in the asymmetric unit was determined by calculating the 
solvent content using the Matthew’s coefficient (Matthews, 1968) program, as a part of 
the CCP4 program suite (Winn et al., 2011). 
2.12.2 Molecular replacement  
The structure of CysK from M. tuberculosis (3ZEI) was retrieved from the protein data 
bank (PDB). A single monomer was extracted from this file, in PyMOL (The PyMOL 
Molecular Graphics System, Version 2.3.2 Schrödinger, LLC) and water and ligands 
were removed. This M. tuberculosis monomer with no ligands and water was used in 
molecular replacement carried out using phenix.phaser (McCoy et al., 2007), from the 
PHENIX suite (Adams et al., 2010). 
2.12.3 Model building and refinement  
The model was initially built and refined using the program phenix.autobuild (Terwilliger 
et al., 2008) from the PHENIX suite (Adams et al., 2010). The resulting structure was 
further built manually using the program COOT (Emsley & Cowtan, 2004). For manual 
building and refinement in COOT, the 2Fo-Fc and Fo-Fc electron density maps, were set 
to 1σ and 3σ, respectively. After each round of structure manipulation, phenix.refine and 
phenix.autobuild were used to run rounds of real-space refinement (Terwilliger et al., 
2008).  
2.12.4 Structural analysis  
Images of the model and maps were generated using programmes PyMOL (The PyMOL 
Molecular Graphics System, Version 2.3.2 Schrödinger, LLC) and COOT (Emsley & 
Cowtan, 2004). Comparing structures was conducted through calculating root mean 
square distances (r.m.s.d) using alignment tool in PyMOL. The surface area and buried 
residue calculations for the trimer/hexamer interfaces were carried out using PDBePISA 
(Krissinel & Henrick, 2007). ENDscript 3.0 was used to identify secondary structural 
features (Robert & Gouet, 2014), alongside visual inspection in PyMOL. 
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2.13 Cysteine synthase complex formation 
The protocol for forming the cysteine synthase complex (CSC) was based on a method 
by (Benoni et al., 2017b). CysK as per section 2.4 and CysE were purified individually 
before being used for CSC formation.  
2.13.1 Purification of CysE 
CysE was purified using IMAC and gel filtration chromatography as per section 2.4.1 and 
2.4.2 with minor modifications by Keely Oldham. CysE pellets were resuspended and 
purified as per section 2.2.4 in Keely Oldham’s thesis (Oldham, 2020), buffer 
compositions found in appendix B.2. 
2.13.2 Formation of the cysteine synthase complex 
2.13.2.1 Monitoring cysteine synthase complex formation by gel filtration 
chromatography 
CysK was freshly purified as per section 2.4.1 and 2.4.2 and CysE was freshly purified 
as per section 2.13.1. A 1 ml solution of CysE 6 µM: CysK 4 µM (monomer ratios) was 
manually injected into the injection loop of the FPLC for injection into the Enrich 650 
analytical gel filtration column (Bio-Rad Laboratories, USA), preequilibrated in gel 
filtration buffer (50 mM Potassium phopshate pH 7.0, 100 mM NaCl) with a flow rate of 
1 ml.min-1. After sample injection, 28 ml gel filtration buffer was run at 1 ml.min-1 
through the column. Fractions were collected and run on a 12% SDS PAGE gel. This was 
repeated with a CysE 4 µM: CysK 0.05 µM 1 ml solution, without fractions being run on 
a 12% SDS PAGE gel.    
2.13.2.2 Monitoring cysteine synthase complex formation by fluorescent 
spectroscopy 
CysK was freshly purified as per section 2.4.1 and 2.4.2 (buffers used were pH 8.0 rather 
than 7.0), and CysE was freshly purified using gel filtration chromatography as per the 
method in section 2.13.1.  300 µl of CysK was added to a quartz cuvette and an excitation 
wavelength scan from 350-550nm was completed using a fluorometer (alphatech, F-7000 
Fluorescence Spectrophotometer) determining the excitation wavelength to be 400nm. 
An emission wavelength scan from 350-600nm determined the emission wavelength to be 
494.6nm. 75 µl CysE was added to the quartz cuvette to give a CysK 4: CysE 1 monomeric 
ratio and the emission wavelength was measured at the time of addition and two minutes 
after. More CysE was subsequently added to give ratios CysK:CysE, 2:1, 1:1 and 2:3, all 
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of which the emission wavelength was measured in the same manner stated above using 
a fluorometer (alphatech, F-7000 Fluorescence Spectrophotometer). Emission peaks, the 
apex wavelength and the corresponding intensities were obtained using FL Solutions 2.1 
for F-7000 and spectra plotted using GraphPad Prism (version 8.2.0, Windows, GraphPad 
Software, La Jolla California USA).   
2.13.2.3 Cysteine synthase complex formation using the CysE C-terminal 
tetrapeptide 
CysK and the CysE C-terminus tetrapeptide inhibitor were thawed. 350 µl of 0.8 mg.ml-1 
CysK was added to a quartz cuvette and an excitation wavelength scan from 350-550nm 
was completed using a fluorometer (alphatech, F-7000 Fluorescence Spectrophotometer) 
determining the excitation wavelength to be 386.2nm. An emission wavelength scan from 
350-600nm determined the emission wavelength to be 471nm. 5.7 µl of 0.2 mg.ml
-1 CysE 
tetrapeptide (final quantity of peptide added, 2176.563 pmol) was added to 350 µl of 0.8 
mg.ml-1 CysK (final quantity of enzyme added, 8706 pmol) in a quartz cuvette (creating 
a 4:1 molar ratio of CysK monomer to peptide) and the emission wavelength measured at 
addition of the peptide and 2 mins after using a fluorometer (alphatech, F-7000 
Fluorescence Spectrophotometer). An additional 5.7 µl of 0.2 mg.ml-1 CysE C-terminus 
tail four peptide inhibitor was added (giving a 2:1 ratio of CysK to peptide) and emission 
wavelength measured as above using a fluorometer (alphatech, F-7000 Fluorescence 
Spectrophotometer).  11.4 µl of 0.2 mg.ml-1 CysE C-terminus tail four peptide inhibitor 
was subsequently added to give various molar ratios (CysK:CysE peptide, 1:1, 1:2, 1:3, 
1:4, 1:5), and emission wavelengths measured at addition of peptide and 2 mins after for 
each molar ratio. All measurements were taken whilst mixing occurred in the cuvette. 
Emission peaks, the apex wavelength and the corresponding intensities were obtained 
using FL Solutions 2.1 for F-7000 and spectra plotted using GraphPad Prism (version 
8.2.0, Windows, GraphPad Software, La Jolla California USA).   
2.14 cysK genomic deletion in Neisseria gonorrhoeae   
2.14.1 Agarose gel electrophoresis 
Agarose gels were made as per Appendix C and a 10 well comb was inserted into the top 
of the gel, before leaving to set at room temperature ~30 mins.  After PCR, 10 µl of each 
PCR product were mixed with 2 µl of 6x loading dye (Appendix C) using a pipette. Mixed 
samples were loaded into a 1% agarose gel (HydraGene LE Agarose) made with 1x TAE 
Buffer (Appendix C) and run in a dedicated OWL electrophoresis tank (ThermoFisher 
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Scientific) containing 1x TAE (Appendix C) with a LighteningVolt OSP250-L 
electrophoresis machine (Biolab scientific) at 100V for 40 minutes at room temperature. 
Samples were run together with 7 µl of Invitrogen 1kb+ ladder (Appendix C). The gel 
was imaged using an Omega Lum™ gel imager (Aplegen, USA).  
2.14.2 PCR to check for homologous recombination 
The DNA template for homologous recombination was designed using Geneious Prime 
(Biomatters) to contain 150 bp of flanking sequence (corresponding to 150 bp upstream 
and downstream of the cysK gene respectively) either side of a kanamycin resistance gene 
(kanR). The DNA construct was ordered as a Geneblock from Twist Bioscience (USA). 
Lyophilised DNA was resuspended in TE buffer to a final concentration of 20 ng.µl-1 for 
use as a DNA template in subsequent PCR reactions. Primers were designed using 
Geneious Prime (Biomatters) to amplify the entire DNA construct (CysK KO FWD: 
5’-TTGTCACTGAAGCGGGAAGG-3’ and CysK KO REV: 
5’-CCTTCCCGCTTCAGTGACAA-3’) and ordered from IDT (USA). Primers were 
resuspended in TE buffer to 100 µM and working stocks made by diluting in MQ water 
to 10 µM.  
 
PCR master mix was set up as follows: 20 µl Hotfire Pol MasterMix, 3 µl CysK PCR 
Forward primer (10 mM), 3 µl CysK PCR Reverse primer (10 mM), 69 µl Ultra Distilled 
H2O were added together into a 1.5 ml Eppendorf tube. 19 µl of this mixture was removed 
and added to a PCR tube and 1 µl of Ultra distilled H2O was added to produce a negative 
control. 4 µl of DNA template (CysK KanR KO ordered from TWIST and resuspended 
in 1x TE buffer) was added to the master mixture. 20 µl of master mix with the DNA 
template was aliquoted into four PCR tubes. The five PCR tubes were added to BioRad 
DNA Engine using the following cycling conditions: 
 
PCR Protocol 
95 ºC   15 min 
95 ºC   20 sec 
55 ºC   30 sec 
72 ºC   1.5 min 





PCR products were purified using a Roche-applied-science DNA purification kit 
according to manufacturer’s instructions and run on an agarose gel to check purity as per 
section 2.14.1.  
2.14.3 Measuring Nucleic acid (DNA) concentration NanodropTM 
Nucleic acid concentration was determined by NanodropTM 2000 (Thermofisher, USA). 
2.14.4 N. gonorrhoeae plate transformations 
Purified PCR DNA products were pooled and combined with Ultra Distilled water to a 
final concentration of 20 ng.µl-1 in 50 µl. Two 10 µl amounts of PCR product were spotted 
onto GCB agar (Appendix C) and left to soak in to the agar and dry. This was repeated 
onto New York agar (Fort Richards, New Zealand). An N. gonorrhoeae colony was taken 
from fresh GCB agar and streaked across the plates through each spot of DNA and 
incubated at 37 ºC for 48 hours. Single colonies that grew within the spotted DNA circles 
from both GCB and New York agar were streaked onto GCB agar supplemented with 50 
µg.ml-1 kanamycin and incubated at 37 ºC for 48 hours to select for integration of the 





Results and Discussion 
3.1 Kinetic characterisation of O-acetylserine sulphydrylase/CysK 
from N. gonorrhoeae enzyme  
3.1.1 CysK kinetic analysis and enzyme mechanism 
O-acetylserine sulfhydrylase (CysK/ OASS-A, EC:2.5.1.47) is a key enzyme in the 
biosynthesis of cysteine in bacteria and plants. It catalyses the final step of the two-step 
cysteine biosynthesis reaction (Figure 1.2). OASS is a member of the tryptophan synthase 
β-superfamily (Fold type II) and the β-family of PLP dependent enzymes (Mino & 
Ishikawa, 2003; Guédon & Martin-Verstraete, 2007; Takumi & Nonaka, 2016). Many 
bacteria have two OASS isoforms; OASS-A/CysK and OASS-B/CysM. Both isoforms 
catalyse the same reaction, with OASS-A using sulphide and O-acetylserine to synthesis 
cysteine and OASS-B using thiosulphate in place of sulphide to give cysteine 
thiosulfonate as a product.  
 
The kinetic mechanism of OASS-A is bi-bi ping-pong with a stable aminoacrylate 
intermediate. OAS binds to the internal aldimine of the enzyme and acetate is released as 
the first product forming the aminoacrylate intermediate. Bisulphide enters the active site 
attacking as the second substrate, and L-cysteine is released as the final product (Figure 
1.10) (Rabeh & Cook, 2004; Joshi et al., 2019). OASS-A activity is inhibited by binding 
to serine acetyltransferase (the first enzyme in the two-step pathway) to form the cysteine 
synthase complex (CSC) across many species (Saito et al., 1995; Zhao et al., 2006; 
Benoni et al., 2017b). The OASS-B isoform does not bind to serine acetyltransferase and 
therefore does not form the cysteine synthase complex (Zhao et al., 2006).  
 
Given the elucidated mechanism, inhibition and family similarities in CysK enzymes 
across species, we predict that CysK from N. gonorrhoeae will have O-acetylserine 
sulfhydrylase activity. CysK is being characterised as a new antimicrobial target for other 
bacterial pathogens and (Salsi et al., 2011; Franko et al., 2018; Joshi et al., 2019) given 
the rapid emergence of antimicrobial resistance in N. gonorrhoeae we propose that CysK 
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is a good target for new antimicrobial design for treatment of antimicrobial-resistant 
N. gonorrhoeae.  
 
Inhibitor design relies on a detailed understanding of enzyme structure and mechanism. 
This section biochemically characterises CysK to understand the enzyme kinetics and 
mechanism of action.  
3.1.2 Expression and purification of CysK 
To successfully characterise CysK from N. gonorrhoeae, active and soluble protein was 
purified. Prior to the start of this MSc research, Dr Joanna Hicks had cloned cysK from 
N. gonorrhoeae into the expression plasmid pET28b for expression with a C-terminal 
His-tag in E. coli (Section 2.3 and 2.4).  
 
CysK was successfully purified by IMAC and gel filtration chromatography as per 
method 2.4. The IMAC purification chromatogram in Figure 3.1a shows CysK elutes at 
~20% elution buffer (200 mM of imidazole). The corresponding SDS-PAGE gel of the 
IMAC fractions, demonstrates that the majority of contaminating E. coli protein present 
in the supernatant is removed during IMAC purification (Figure 3.1b). This results in 
relatively pure CysK protein of approximately 33 kDa (Figure 3.1b, blue arrow) 
consistent with the predicted molecular weight of the CysK monomer (32.726 kDa, 
calculated as per section 2.4.4). Fractions containing IMAC purified CysK (Figure 3.1, 
green bar) were measured for protein concentration and used for gel filtration purification 































Figure 3.1: IMAC Purification of CysK. (a) IMAC chromatogram of A280 nm shows volume (ml) (X-axis), 
absorbance 280nm (left Y-axis) and concentration of elution buffer (%B) (right Y-axis). Data from protein 
loading between 0-20 ml has been excluded for scaling purposes. (b) 12% SDS-PAGE gel of CysK IMAC 
purification. CysK protein (32.726 kDa) is labelled with a blue arrow and is present in all samples (the 
insoluble pellet (P), the soluble supernatant (S), and the IMAC fractions (green bar)). Molecular weights of 
Precision Plus Protein Standards (L) in kDa are labelled. Purification was carried out at room temperature.  
 
IMAC-purified CysK underwent a final purification step via gel filtration 
chromatography (section 2.4.2). CysK eluted as a single peak from an Enrich 650 
analytical gel filtration column with an elution volume of 14.2 ml (Figure 3.2a, purple 
bar). Using the Enrich 650 calibration curve (Appendix B.2), the apparent molecular 
weight from the elution volume is 52.862 kDa. The predicted molecular weight of the 
CysK monomer is 32.726 kDa, which suggests that CysK elutes as a dimer 
(52.862/32.726 = 1.62). No protein was present in the void volume of the column (10.56 
ml) indicating that CysK did not aggregate and remained soluble during purification. The 
corresponding SDS-PAGE gel of the gel filtration column show pure CysK protein of 











































Figure 3.2: Gel filtration purification of CysK. (a) Enrich 650 gel filtration chromatogram shows elution 
of a large peak at 14.2 ml. (b) 12% SDS-PAGE gel shows high yield and purity of CysK (purple bar). CysK 
protein (32.726 kDa) is labelled with a blue arrow and is present in all samples (the insoluble pellet (P), the 
soluble supernatant (S), and the Gel Filtration fractions (purple bar)). Molecular weights of Precision Plus 
Protein Standards (L) in kDa are labelled. Purification was carried out at room temperature.  
3.1.3 Assay optimisation 
I developed an assay to measure the enzyme activity of CysK from N. gonorrhoeae based 
on a method for quantifying cysteine produced in a stopped assay (Gaitonde, 1967). Acid 
ninhydrin reacts with cysteine forming a pink chromophore measurable at 560 nm, 
indicative of the amount of cysteine present in a reaction.  
 
All assays were carried out in MOPs buffer (100 mM, pH 7) at 37 ºC.  Assays were set 
up as per section 2.5.1. No NaCl was present during purification of the enzyme, or in 
assay buffers as chloride ions inhibit activity of CysK (Burkhard et al., 2000; Campanini 
et al., 2005). All raw data collected is listed in Appendix B.5. 
3.1.3.1 Optimisation of enzyme (CysK) concentration  
Initially, trial assays were completed to determine an appropriate concentration of CysK 

























state (linear rate) across varied OAS and Na2S concentrations. Assays were set up using 
3 mM Na2S and 50 mM OAS based on saturating substrate concentrations for CysK from 
Arabidopsis thaliana (Bonner et al., 2005). Na2S is used for supply of the required S
2- ion 
in the cysteine biosynthesis reaction. The following concentrations of CysK were trialled: 
0.0058, 0.058, 0.58, 5.8 and 58 mg.ml-1. Each enzyme concentration’s absorbances were 
measured in duplicate and incubated for 15 minutes at 37 ºC. A concentration of 0.58 µg 
was optimal for obtaining steady state rates for use in future kinetic assays (Figure 3.3). 
 
Figure 3.3: Determination of CysK concentration for use in kinetic assays. Concentrations of CysK 
measured include: 0.0058, 0.058, 0.58, 5.5 and 58 µg. Duplicates for each concentration were collected. 
Error bars represent standard error. 
3.1.3.2 Optimisation of enzyme storage 
Following the lack of activity seen in week old CysK enzyme, the literature was 
interrogated for possible solutions for increasing stability, therefore maintaining long 
term activity of the enzyme. It is well documented for addition of 50% (v/v) glycerol to 
enzyme aliquots significantly improves stability the enzyme upon freezing (Vagenende 
et al., 2009). Thus, glycerol was incorporated for -80 ºC freezer storage. Two 1 ml 
aliquots of 0.8466 mg.ml-1 CysK, 25% (v/v) glycerol final concentration were made and 
stored at -80 ºC. An aliquot was thawed and CysK activity measured using 10 mM OAS 
and 1.5 mM Na2S (Bonner et al., 2005) at 0.8466 mg.ml
-1 and 1.6932 mg.ml-1 CysK 
concentration. Absorbance readings indicated no freeze/thaw effect decreasing the 
activity of CysK (Table 3.1), resulting in storage of CysK aliquots (~ 0.8 mg.ml-1) in 25% 






Table 3.1: CysK glycerol (0.8 mg.ml-1, in final concentration 25% glycerol) aliquot activity testing assay 
Blank 0.8466 mg.ml-1 (1 µl) 1.6932 mg.ml-1 (2 µl) 
0.040 0.200 0.382 
0.043 0.175 0.293 
3.1.3.3 Optimisation of reducing agent 
Initial activity assays were conducted by varying the concentration of Na2S from 
0.004-1.5 mM based on concentrations used by (Bonner et al., 2005), holding the OAS 
final concentration at 10mM (saturating). Initial assay data (Appendix B.5) indicated no 
activity. Dithiothreitol (DTT, 100 mM, pH 7) was made fresh, 10 µl was added post-assay 
and incubated at room temperature for 30 minutes to reduce any cystine present to 
cysteine, as cystine is not detected by the acid ninhydrin method.  
 
To alleviate the 30-minute room temperature incubation with DTT, the DTT reducing 
agent was replaced by a new reducing agent TCEP (Tris (2-carboxyethyl) phosphine 
hydro-chlorine). TCEP is known to effectively reduce substances in 5 min when added at 
a 1.5 times concentration to the substance being reduced and is able to be stored at room 
temperature for longer periods of time before oxidising (Hampton Research Solutions for 
Crystal Growth; Thermo Fisher Scientific, 2013).  
 
Assays where the concentration of Na2S was varied between 0.004-1.5 mM were 
performed using TCEP added to the assay reaction at a final concentration of 8mM, 
however, the results were inconclusive as absorbance readings (Appendix B.5) for each 
reaction condition indicated no activity, reading the same as both the blank and negative 
control conditions. CysK activity was tested without the presence of a reducing agent, 
indicating the enzyme was still active and TCEP optimisation was necessary (Appendix 
B.5).  
 
Five different reaction conditions were set up to measure the ability of TCEP to reduce 
cystine to cysteine using a solution of 5 mM cysteine that had been left at room 
temperature for 14 days therefore converting to cystine. Reaction conditions included: no 
cysteine, no TCEP and addition of 8 mM TCEP (final concentration) after incubation for 
30 sec, 5 min and 10 min, respectively. No enzyme or substrates were included in these 
assays, so we could observe the effect of the TCEP reducing agent vs no reducing agent. 
Results showed the reaction with no TCEP added had the highest absorbance (indicating 
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the highest cysteine concentration) and irregular, significantly lower absorbance readings 
were observed in all three 8 mM TCEP conditions, regardless of incubation time 
(Appendix B.5). With TCEP added as a reducing agent, we would expect these samples 
to have the highest absorbance and increase over time, indicating a higher cysteine:cystine 
ratio.  
 
Therefore, the TCEP activity test was repeated with minor modifications. TCEP was 
added at a final concentration of 50 mM and the pH of the cysteine solution was adjusted 
to pH 2.  Eight different assay conditions were set up to measure the ability of TCEP to 
reduce cystine to cysteine using a solution of 5 mM cystine (a 5 mM cysteine solution 
that had been left at room temperature for 14 days therefore oxidising to cystine). 
Reaction conditions included: no cysteine, no TCEP and 50 mM TCEP with incubation 
for 30 sec, 5 min and 10 min respectively, and 50mM TCEP with a fresh 5 mM solution 
of cysteine. Again, no enzyme or substrates were included in these assays. Surprisingly, 
the fresh L-cysteine did not react with the acid ninhydrin added, giving absorbance 
readings equivalent to the blank samples. The cystine solution however, produced a 
similar pattern observed previously (Appendix B.5), the condition with no TCEP gave 
the highest absorbance reading, whilst the conditions with TCEP gave irregular and 
significantly lower absorbance readings.  
 
Subsequently, assays without TCEP present and 6.32 µg of CysK were conducted to 
determine the approximate amount of cysteine produced using the cysteine standard curve 
(Appendix B.2). Following this, three sets of assays with 9.17, 2.478 and 1.626 µg of 
CysK respectively were conducted using final concentration 30 mM TCEP (Appendix 
B.5). These were all inconclusive, giving irregular absorbance readings with extremely 
high standard deviations making it impossible to draw accurate conclusions.  
 
Review of the literature surrounding TCEP in these cysteine determination assays, 
indicated three issues. Desulphurisation of cysteine containing compounds occurs in the 
presence of TCEP when heated to 60 ºC, resulting in conversion of cysteine to alanine 
(Wang et al., 2010). TCEP is also unstable in phosphate buffers (Thermo Fisher Scientific, 
2013) and cannot be used in the presence of high protein concentration (defined as 
6 mM +) (Melnikova et al., 2019). The CysK enzyme is purified in a potassium phosphate 
buffer and the assay method has an incubation step at 95 ºC that is significantly higher 
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than 60 ºC. We therefore hypothesised that the lack of enzyme activity in our assays was 
due to the conversion of cysteine to alanine during the 5 min 95 ºC incubation step, which 
would be unable to react with the acid ninhydrin reagent to produce the pink chromophore 
that absorbs at 560 nm. Therefore, comparisons of different reducing agents in activity 
assays were compared to determine which reducing agent should be used in cysteine 
determination assays. Six reaction conditions were trialled: 30 mM TCEP, 30 mM DTT, 
no reducing agent (NRA) and blanks for each reducing agent condition (blanks had no 
enzyme added). Assays were conducted at saturating substrate concentrations of 10 mM 
OAS and 10 mM Na2S with 2.4 µg of CysK. Higher concentrations of CysK were used 
in these reducing agent assays to allow for higher cysteine production hopefully making 
comparisons between reducing agents more stated.  Reactions were set up without the 
addition of reducing agent and once all reactions were stopped by addition of 20% TCA, 
the reducing agents were added (TCEP, DTT and NRA) to a final concentration of 30 
mM (addition of MOPS buffer in the NRA condition). All conditions were incubated at 
room temperature, and the assay method followed as per section 2.5.1. Absorbance 
readings indicated a stark contrast between the reducing abilities of TCEP and DTT in 
these assays (Table 3.2), with TCEP absorbance readings approximately half that of the 
DTT reducing agent absorbance readings, the NRA also had higher absorbance readings 
compared to TCEP (Table 3.2). Thus, it was established that DTT would be used in all 
cysteine determination assays from this point. 
Table 3.2: Reducing agent efficacy testing absorbance readings at 560nm. TCEP, DTT and NRA tested as 
reducing agents. 
 Reaction 1 Reaction 2 
TCEP (blank) 0.048 0.050 
DTT (blank) 0.051 0.052 
NRA (blank) 0.047 0.049 
TCEP (30 mM) 0.513 0.531 
DTT (30 mM) 1.153 0.961 
NRA 0.669 0.619 
3.1.3.4 Final assay optimisation 
The assay method was redesigned accommodating the use of 100 mM DTT to give a final 
concentration of 30 mM in the reducing step as per section 3.1.3.3. Assays were set up as 
per section 2.5.1 with minor modifications outlined below. The addition of 39 µl 100 mM 
DTT to all reactions resulting in 130 µl final volume.  
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Preliminary results were more promising than previous assays, showing consistent 
activity across different varied OAS concentration conditions, however, outliers were still 
present with blank activity compared to their duplicates (Appendix B.5). After the 95 ºC 
incubation step, the reaction solution overflowed over the reaction wells. To alleviate 
these outliers and the overflow, three modifications to the method were introduced. 
(1) The concentration of the DTT stock solution was doubled to 200 mM, changing the 
DTT and MOPs volume added to 16.5 and 3.5 µl respectively with a final volume of 110 
µl. This change in volume prevented overflow during the 95 ºC incubation step, therefore 
preventing potential loss of cysteine produced during the reaction. (2) The concentration 
of Na2S was increased from 1 mM to 10mM to ensure saturating concentrations of Na2S. 
(3) The frozen CysK stocks (0.8 mg.ml-1 CysK, 25% v/v glycerol) were aliquoted into 
multiple tubes and stored at stored at -80 ºC to eliminate the effects of freeze thawing. 
These changes resulted in reliable, reproducible enzyme activity data. 
 
All rates for kinetic analysis were taken from the linear section of each reaction (the first 
five minutes), indicating that the steady state for calculating enzyme rate in these stopped 
assays occurs in the first five minutes across all substrate concentrations (Appendix B.5). 
Thus, all assays were shortened to measure activity over 10 minutes rather than 20 with 
time points at 0, 2.5, 5, 7.5 and 10 minutes rather than the original 0, 5, 10, 15 and 20 
minutes.  
3.1.4 CysK kinetic analysis 
Enzyme kinetic curves were collected for both substrates, OAS and Na2S for the purpose 
of determining KM and Vmax for CysK. These kinetic parameters provide insights into the 
enzyme’s affinity for these substrates and can be used to calculate measures of catalytic 
efficiency including, kcat and kcat/KM.  
  
Assays varying the concentration of substrate OAS were conducted as per the final 
parameters in section 3.1.3.4. Rates (mM.min-1) were calculated as per section 2.5.1 and 
plotted against increasing OAS concentrations (0.2 – 10 mM) at saturating concentrations 
of Na2S (10 mM). The resulting non-linear regression Michaelis-Menten plot 
(R2 = 0.7428, Figure 3.4, red line) does not follow a linear increase of rate as substrate 
concentration rises, however, showing a sigmoidal rate increase. This indicates an 
alternate kinetic model may be more accurate for CysK. Subsequently, a non-linear 
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regression allosteric sigmoidal model of catalysis (Equation 2.4) was fit (R2 = 0.8641, 
Figure 3.4, blue line) to the data. 
 
Figure 3.4:  CysK activity with varying OAS concentration. Red line shows non-linear regression fit of the 
Michaelis Menten equation. Blue line shows a non-linear regression fit of an allosteric sigmoidal equation 
(occurs when the enzyme has cooperative subunits). Na2S was held at a constant concentration of 10 mM.. 
Assay reactions were conducted at 37 ºC. All reaction conditions were collected in duplicate. Error bars 
represent standard error.  
 
Table 3.3: Summary of kinetic parameters for initial OAS data. Values are means calculated from 
duplicates and are quoted with standard error. kcat values are reported for the CysK dimer.   
 Michaelis-Menten Allosteric Sigmoidal 
vmax (mM.min-1) 0.039 ± 0.005 0.032 ± 0.002 
KM (mM) 1.223 ± 0.474 - 
Khalf (mM) - 0.911 ± 0.104 
kcat (s-1) 7036 ± 902 5844 ± 362 
kcat/KM (mM.s-1) 5753 ± 1475 6417 ± 796 
h - 3.076 ± 0.953 
R2 0.7428 0.8641 
 
The allosteric sigmoidal model, is a co-operative model, which occurs in enzymes with 
multiple binding sites and is defined by increased affinity of an active site for a ligand, 
when a ligand binds to another active site (Libretexts, 2020b, 2020a). An enzyme that 
demonstrates cooperativity is defined as allosteric and can demonstrate either positive or 
negative cooperativity. Positive cooperativity occurs when a ligand binding to an 
enzymes active site increases the affinity of one of the enzymes alternate active sites for 
a ligand, ultimately causing a rapid and co-ordinated increase in the reaction rate as the 




Whereas, negative cooperativity occurs when the ligand binding causes a decreased 
affinity in one of the enzymes alternate active sites for the ligand, ultimately causing a 
slowed reaction rate (an allosteric hyperbolic model) (Libretexts, 2020b, 2020a). Figure 
3.4 shows an allosteric sigmoidal kinetic profile with a good fit (R2 = 0.8641, Figure 3.4, 
blue line), and characteristic of this model, low enzyme activity at low OAS substrate 
concentration with a rapid and immediate increase in activity to the Vmax as OAS 
concentration increases. The kinetic parameters quoted for the allosteric sigmoidal model 
also display significantly less error than the Michaelis-Menten kinetic model (Table 3.3). 
Thus, indicating OAS exhibits positive cooperativity in N. gonorrhoeae’s CysK dimer.  
 
OASS-A enzymes display a wide variety of kinetic profiles in relation to OAS. Similar 
to the N. gonorrhoeae OASS-A (CysK) characterised here, the OAS kinetic profile for 
Datura innoxia OASS isozyme C (three OASS isozymes A-C were isolated) at low 
concentrations of OAS, exhibits positive cooperativity (allosteric sigmoidal model). 
However, although we did not measure activity at OAS concentrations higher than 10 
mM, OAS does exhibit competitive inhibition at concentrations higher than 25 mM in 
D. innoxia (Kuske et al., 1994). Interestingly, both Phaseolus vulgaris and 
Phaseolus polyanthus OASS-A display a standard Michaelis-Menten relationship to OAS 
(Bertagnolli & Wedding, 1977), in which the reaction rate increases linearly in relation 
to substrate concentration until a maximal point at which activity levels off at Vmax 
(Libretexts, 2020c). Thus, resulting in an asymptotic rectangular hyperbolic curve. 
Alternatively, the S. typhimurium OASS-A enzyme, exhibits substrate inhibition for OAS 
at concentrations above 7.5 mM where enzyme activity decreases (Cook & Wedding, 
1976; Tai et al., 1993). Assays where the concentration of Na2S was varied were 
conducted as per the final parameters in section 3.1.3.4. Rates (mM.min-1) were calculated 
as per section 2.5.1 and plotted against increasing Na2S concentrations (0.2 – 12 mM) at 
saturating concentrations of OAS (10 mM). The first six Na2S concentrations (0.2 - 2 mM) 
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show virtually no enzyme activity (Figure 3.5), therefore not adhering to the typical 
Michaelis-Menten kinetic model (R2 = 0.5380, Figure 3.5, red line). The sigmoidal  
Figure 3.5: CysK activity with varying Na2S concentration. Kinetic mechanisms modelled for varying 
Na2S concentrations. Red line shows a non-linear regression fit of Michaelis-Menten kinetic model. Dotted 
black line shows a non-linear regression fit of substrate inhibition kinetic model. Blue line shows a 
non-linear regression fit of an allosteric sigmoidal (cooperativity) kinetic model. All models fit using the 
same data. OAS was held at a constant concentration of 10 mM (saturating). CysK was freshly thawed for 
these assays. Assay reaction was conducted at 37 ºC. All reaction conditions were collected in duplicate. 
Error bars represent standard error. 
shape of the rates from 0.2 – 7 mM Na2S suggest similar positive cooperativity to the 
OAS kinetic profile. Hence, an allosteric sigmoidal model (R2 = 0.7728, Figure 3.5, blue 
line) was fit, giving a Khalf and Vmax of 3.933 ± 224.517 mM and 0.035 ± 0.003 mM.min
-1, 
respectively (Table 3.4). Despite the improved fit, the distinct lack of a plateau, indicated 
some form of inhibition was present at Na2S concentrations higher than 7 mM. Therefore, 
a substrate inhibition model (R2 = 0.6190, Figure 3.5, dotted black line) was fit to the data, 
giving a KM and vmax of 14014.449 ± 4.743x10
7 mM and 97.924 ± 331330.28 mM.min-1, 
respectively (Table 3.4). Given the error present for the Khalf in the allosteric sigmoidal 
model exceeds both the Khalf value quoted, and the concentration ranges plotted, this was 
deemed not scientifically relevant. Combined with the relatively poor goodness of fit 
(R2 = 0.7728), it was clear this model was not accurate or scientifically relevant. The KM 
and Vmax values quoted for the substrate inhibition model are incredibly large and exceed 
the concentration ranges plotted by a huge margin, indicating these to also not be 
scientifically relevant. Despite these conclusions, it is possible both positive cooperativity 





Table 3.4: Summary of kinetic parameters for Na2S data fit with Michaelis-Menten, allosteric sigmoidal 
and substrate inhibition models. Values are means calculated from duplicates and are quoted with standard 
error. kcat values are reported for the CysK dimer.   
 Michaelis-Menten Allosteric Sigmoidal Substrate Inhibition 
vmax (mM.min-1) 0.056 ± 0.027 0.053 ± 0.003  97.924 ± 331330.028  
KM (mM) 7.021 ± 6.676 - 14014.449 ± 4.743x107 
Khalf (mM) - 3.933 ± 224.517  
Ki - - 0.006 ± 20.589 
kcat (s-1) 10132 ± 4891 6319 ± 543 17738023 ± 6x1010 
kcat/KM (mM.s-1) 1443 ± 1393 1607 ± 276 1266 ± 8565045 
h - 50.66 ± 171493.243 - 
R2 0.5380 0.7728 0.6190 
 
Therefore, the substrate inhibition and allosteric sigmoidal model equations were 
combined (Equation 2.6) and fit to the data (R2 = 0.9573, Figure 3.6). This model fit the 
data relatively well, however, the Hill co-efficient value indicates the inaccuracy of the 
model. A hill co-efficient of 4.159 ± 0.854 (Table 3.5) suggests the enzyme is functioning 
as a tetramer, which is incorrect as CysK has been established as a dimer through gel 
filtration as per section 3.1.2. It was impossible to fit any simple model of substrate 
inhibition, Michaelis-Menten or allosteric sigmoidal kinetics to the profile. The initially 
allosteric sigmoidal curve did not smoothly approach an asymptote, instead abruptly 
decreasing due to substrate inhibition. It is this abrupt decrease in activity past 7 mM 
Na2S that makes it difficult to fit any particular model to the data. Due to this, the kinetic 
constants obtained from the combined allosteric sigmoidal with substrate inhibition 
model are not particularly accurate, as was the case with both the P. vulgaris OASS-A 
and D. innoxia OASS (isozyme A and C) enzymes (Bertagnolli & Wedding, 1977; Kuske 





Figure 3.6: Constrained non-linear regression fit of an allosteric sigmoidal substrate inhibition model for 
Na2S. OAS was held at a constant concentration of 10 mM (saturating). CysK was freshly thawed for these 
assays. Assay reaction was conducted at 37 ºC. All reaction conditions were collected in duplicate. Error 
bars represent standard error.  
Interestingly, the P. vulgaris OASS-A, shows substrate inhibition after reaching its 
maximal rate at approximately 1.5 mM S2-. However, positive cooperativity (an allosteric 
sigmoidal model) is observed at concentrations lower than 0.3 mM (Bertagnolli & 
Wedding, 1977). Alongside this, D. innoxia OASS (isozyme C) exhibits an allosteric 
sigmoidal (positive cooperativity) response to S2- at concentrations below approximately 
0.18 mM with substantial substrate inhibition after 0.2 mM S2- concentration (Kuske et 
al., 1994). Both, the OASS isoenzyme C from D. innoxia and the OASS-A from 
P. vulgaris display very similar kinetic profiles to N. gonorrhoeae’s for Na2S, initially an 
allosteric sigmoidal model, followed by strong substrate inhibition once the maximal rate 
is reached (Bertagnolli & Wedding, 1977; Kuske et al., 1994). Alternatively, 
P. polyanthus OASS-A shows no allosteric sigmoidal (positive cooperativity) response 
to S2-, however, fits a substrate inhibition model (Bertagnolli & Wedding, 1977). 
S. typhimurium OASS also shows substantial substrate inhibition after 0.25 mM S2- (Cook 
& Wedding, 1976). Although the organisms P. polyanthus’ OASS-A and 
S. typhimurium’s OASS do not fit the same kinetic profile as N. gonorhoeae’s OASS-A 
(Figure 3.6), both display substrate inhibition in relation to S2-. Substrate inhibition by 
Na2S is observed across many species OASS-A enzymes.   
 
Substrate inhibition occurs with concentrations of Na2S higher than 7 mM (Figure 3.6). 
In earlier assays CysK activity was analysed with varying OAS concentrations with Na2S 




concentrations at 7 mM Na2S to give a more accurate kinetic representation of CysK’s 
utilisation of OAS, removing the potential substrate inhibition that may have been 
contributing in Figure 3.4. Rates (mM.min-1) were calculated as per section 2.5.1 and 
plotted against increasing OAS concentrations (0.2 – 10 mM) at a Na2S concentration of 




Figure 3.7: CysK activity with varying OAS concentration in the presence of 7 mM Na2S. Allosteric 
sigmoidal (cooperativity) model fit to the data. CysK was freshly thawed for these assays. Assay reaction 




Table 3.5: Summary of enzyme kinetic parameters for substrates OAS and Na2S. Values are means 
calculated from duplicates and are quoted with SEM. kcat values are reported for the CysK dimer. 
 
 OAS  Na2S 
vmax (mM.min-1) 0.038 ± 0.001 2.530 ± 4.601  
KM (mM) - 12.430 ± 8.133 
Khalf (mM) 1.01 ± 0.066 - 
Ki - 5.146 ± 5.012 
kcat (s-1) 6907 ± 181 458360 ± 833426 
kcat/KM (mM.s-1) 6271 ± 329 36875 ± 134097 
h - 4.159 ± 0.854 






Table 3.6: Comparison of kinetic parameters amongst CysK homologues. Assay methods to measure 
cysteine produced are varied. 560nm/546nm = absorbance of cysteine at 560nm or 546nm wavelength, TNB 
412nm = monitoring the disappearance of TNB at 412nm wavelength, Electrode S2- = electrode used to 
measure depletion of sulphide ions (S2-), - = not reported. kcat values are reported for the CysK dimer. 
 














N. gonorrhoeae  1.01/12.43 6.9x103/458360 6271/36875 7.0, 37 ºC, 
560nm 
This thesis 








D. innoxia (isozyme 
A) 
5.3/260 - - 7.6, 34 ºC, 
546nm 
(Kuske et al., 
1994) 
D. innoxia (isozyme 
C) 
5.1/80.5 - - 7.6, 25 ºC, 
546nm 
(Kuske et al., 
1994) 




S. typhimurium 1/0.006 - 1.4x108/2.4x1010 7.0, 25 ºC, 
Electrode S2-
/TNB 412nm 
(Tai et al., 1993) 
 
The difference in the KM for Na2S and the Khalf for OAS (12.43 mM Na2S vs. 1.01 mM 
OAS) suggests CysK has a higher affinity for the OAS substrate. The KM (or Khalf) values 
for OAS are comparable with those collected from other CysK homologues (Table 3.6). 
Interestingly the range of KM values collected for Na2S across CysK homologues is 
extensive, most likely due to difficulties encountered in fitting any single kinetic model 
to the Na2S profile. Thus, no accurate comparisons can be made between the 
N. gonorrhoeae KM for Na2S and other CysK homologues.  
 
The catalytic turnover (kcat) values were derived from the Vmax as per section 2.6, 
assuming a dimer of CysK monomers for comparison with literature values. kcat values 
for the CysK homologues in Table 3.6 could not be found. The specificity constant 
(kcat/KM) values were calculated as per section 2.6. The kcat/KM values for CysK OAS and 
Na2S are 6.271x10
3 and 3.688x104, respectively. kcat/KM values of ≥ 10
8 M.s-1 indicate an 
enzyme is diffusion limited, thus, kcat/KM values of 10
3/104, indicate CysK is not diffusion 
limited (Schurr & Schmitz, 1976). These values are however, 100,000 and 1,000,000-fold 
lower than the literature values found for S. typhimurium (Tai et al., 1993). However, due 
to the issues encountered when fitting a model to the Na2S kinetic profile, conclusions 
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cannot be drawn from many of these comparisons without further experimental 
interrogation of the kinetics. 
 
Interestingly, there is a 10-fold kcat/KM increase for Na2S compared to OAS. This, 
however, cannot be attributed to CysK having a greater affinity for Na2S, as based on 
KM/Khalf values CysK has a higher affinity for OAS. The discrepancy in this explanation 
is a result of the difficulty in fitting a model to the Na2S kinetic profile. KM values tend 
to reflect concentrations of substrate observed in the intracellular environment. There are 
currently no reported values for S2- or OAS concentration for Neisseria species. In 
B. subtilis, the intracellular concentrations of OAS have been reported to vary between 
~20 – 200 µM,  depending on whether cells were grown in the presence of methionine or 
cystine (cystine causes lower intracellular concentrations of OAS) (Tanous et al., 2008). 
Assuming a similar intracellular concentration in N. gonorrhoeae, this would give a low 
intracellular concentration to KM ratio for OAS (20-200 µM vs. 1010 µM, intracellular 
concentration vs. OAS KM). This ratio would suggest CysK would not be saturated with 
OAS, likely limiting activity of CysK in vivo (Davidi et al., 2016). The lack of literature 
values for any bacterial intracellular S2- values does not allow for any conclusions about 
the effect Na2S concentrations may have on in vivo CysK activity.  
 
Many studies in the literature confirm that CysK uses a bi-bi ping-pong mechanism (also 
known as a non-sequential mechanism) (Cook & Wedding, 1976; Tai et al., 1993; Rabeh 
& Cook, 2004; Joshi et al., 2019). Based on this reaction mechanism seen in CysK 
homologues, we predict that CysK most likely has a bi-bi ping-pong mechanism, which 
is in keeping with the proposed enzyme:α-aminoacrylate intermediate during nucleophilic 
attack of the sulphide (Joshi et al., 2019). However, it has been reported that S2-, the 
inorganic anion, does not have a binding site within the CysK enzyme as a substrate, 
instead likely adding to the α-aminoacrylate intermediate immediately upon diffusion into 
the active site. An anion binding site has been confirmed with Cl- ions present in CysK, 
causing an inhibited enzyme, however, this allosteric binding site was non-specific, 
accepting a wide array of anions to bind (Tai et al., 2001). The role of S2- in competitive 
substrate inhibition has been found across many species, including D. innoxia, P. vulgaris, 
P. polyanthus and S. typhimurium (Cook & Wedding, 1976; Bertagnolli & Wedding, 
1977; Tai et al., 1993; Kuske et al., 1994). The partial competitive inhibition observed in 
the Na2S kinetic profile of N. gonorrhoeae’s CysK is typical of allosteric inhibitors, 
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indicating that at high S2- concentrations, S2- binds to an allosteric site, resulting in a 
partially inhibited enzyme (Tai et al., 2001). Thus, a slightly alternative mechanism to 
the typical bi-bi ping-pong mechanism is proposed where the S2- binds to an allosteric 
anion-binding site, causing a less active enzyme, however, despite binding of S2- to the 
allosteric site or not, the overall reaction mechanism remains ping-pong (Tai et al., 2001). 
The presence of an allosteric anion binding site explains the partial substrate inhibition 
we observe for Na2S.  
3.1.4.1 Variation of thiosulphate concentration 
Many bacteria have both OASS isoforms, OASS-A/CysK that utilises bisulphide and 
OASS-B/CysM that utilises thiosulphate producing S-sulphocysteine that is converted to 
L-cysteine via an unknown mechanism (Figure 1.2, black dotted line in the bottom left). 
Many bacteria have both isoforms for utilisation in either aerobic or anaerobic conditions, 
however, all Neisseria species have only a single OASS enzyme variant. The single 
Neisseria OASS enzyme appears more homologous to the OASS-A/CysK isoform (Hicks 
& Mullholland, 2018), and from the data presented above is capable of utilising Na2S as 
a substrate. Yet N. gonorrhoeae lacks the ability to produce sulphide via sulphate 
reduction (Hicks & Mullholland, 2018) and can grow on thiosulphate in the absence of 
cysteine. We therefore hypothesised that CysK from N. gonorrhoeae was a 
dual-functioning enzyme capable of utilising both thiosulphate and sulphide for the final 
step in cysteine biosynthesis. Thus, the ability of N. gonorrhoeae CysK to use 
thiosulphate as substrate was tested in a stopped assay as per section 2.7. Multiple 
concentrations (1, 2, 5, 10, 15, 20 and 50 mM) of thiosulphate were tested in the presence 





Figure 3.8: Thiosulphate CysK activity assay non-linear regression fit of a Michaelis-Menten model. OAS 
concentration was held at 10 mM. Assay reactions were conducted at 37 ºC. CysK was freshly thawed. 
Error bars represent standard error.  
 
Non-linear regression fit of a Michaelis-Menten model gave a vmax and KM of 
0.00153 ± 0.0009 mM.min-1 and 5.780 ± 11.476 mM, respectively. The error in the KM is 
greater than the KM itself and takes it to below 0. This, alongside the exceptionally low 
Vmax, which is outside the values measured indicates there was no enzyme activity 
detected for any thiosulphate concentration, thus, indicating CysK from N. gonorrhoeae 
cannot use thiosulphate as a substrate (Figure 3.8).  
3.1.5 CysK kinetics Conclusions and future directions 
The CysK substrates OAS and Na2S both display positive cooperativity (allosteric 
sigmoidal) kinetics, however, Na2S also displays partial competitive substrate inhibition. 
This coincides with the potential presence of an allosteric anion-binding site on the CysK 
enzyme proposed by (Tai et al., 2001). N. gonorrhoeae CysK is unable to utilise 
thiosulphate as a substrate indicating the enzyme may not be a dual-functioning enzyme.  
 
Future work includes investigating the effect higher OAS concentrations has on the 
kinetics of CysK. This will help elucidate the presence of any substrate inhibition that 
may occur, which may also be explained by the presence of the allosteric binding site, 
where the α-carboxylate of OAS binds to the allosteric binding site (Tai et al., 2001). 
Collecting curves of the established reaction with increasing concentrations of Cl- anions 
to observe the potential inhibition is also important for understanding the reaction 
mechanism of CysK. Understanding the reaction mechanism is crucial for computational 




3.2 Structural characterisation of CysK from N. gonorrhoeae 
3.2.1 O-acetylserine sulphydrylase/CysK 
O-acetylserine sulfhydrylase (CysK/OASS-A, EC:2.5.1.47) is a key enzyme in the 
biosynthesis of cysteine in bacteria and plants. OASS-A is a member of the tryptophan 
synthase β-superfamily (Fold type II) and the β-family of PLP dependent enzymes (Mino 
& Ishikawa, 2003; Guédon & Martin-Verstraete, 2007; Takumi & Nonaka, 2016).  
Although structures of CysK from other bacteria have been characterised, there has been 
no investigation into the structure of CysK from N. gonorrhoeae. 
 
We propose CysK is a valid target for the design of new antimicrobial compounds for 
treatment of gonorrhoea. To effectively do this, we require a high-resolution structure of 
CysK (Reichau et al., 2011), which in turn can be used for computational inhibitor 
screening to identify leading compounds for future development. As there is currently no 
determined structure of CysK from N. gonorrhoeae, we aimed to purify, crystallise and 
determine the structure of CysK using X-ray crystallography.  
3.2.2 Crystallisation of CysK 
Prior to the beginning of this master’s research, Annmaree Warrender and I grew 
diffracting CysK protein crystals and collected three datasets from a 2.3 Å crystal as per 
section 2.9. The crystal was obtained from crystallisation condition: 0.1 M HEPES pH 
7.5, 4% polyethylene glycol 400 (v/v), 2.5 M ammonium sulphate.  
3.2.3 CysK data processing  
The data collected was initially indexed in space group 19 (P212121) and a single dataset 
(number 17) used for processing. However, using solely dataset 17 in this space group, I 
was unable to solve the structure, with R values not improving during refinement with 
the best final model having an Rwork/Rfree score of 0.2300/0.3083. The space group was 
subsequently determined to have been incorrectly assigned using zanuda (Lebedev & 
Isupov, 2014) from the CCP4 suite (Winn et al., 2011). The data was subsequently 
reindexed in space group 4 (P1211) (based on zanuda_output), the unit cell dimensions 
changed to match dataset 16 and the two datasets (16 and 17) were integrated and scaled 
using XDS (Kabsch, 2010). Reflections were merged, resolution cut back to 2.49 Å, and 
a FreeR flag dataset for refinement and dataset quality statistics generated (Table 3.7) 
using AIMLESS from the CCP4 suite (Winn et al., 2011). AIMLESS and phenix.xtriage 
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analysis of twinning and tNCS indicated the dataset had a low percentage of twinning 
fraction (0.02), therefore, no attempt to detwin the dataset was made. The following data 
quality thresholds are met by the determined data quality statistics; CC1/2 ≥ 0.3 (0.834), 
I/σI ≥ 2.0 (2.6), Rmerge ≤ 0.8 (0.654) and overall completeness >95% (99.9%) (values in 
the highest resolution shell are reported) indicating the data is of good quality. This data 
was used for downstream processing.  
Table 3.7: Data collection statistics for CysK. Statistics for highest resolution shell are shown in brackets. 
Data statistics generated by AIMLESS and phenix.tableone.  
 
Data Statistic Apo structure  








Mosaicity 0.00  
Monomers in asymmetric 
unit 
4  
Resolution range (Å) 47.53-2.49 (2.58-2.49) 
Numbers of observed 
reflections  
330233 (32079) 
Number of unique 
reflections 
47132 (4605) 
Rmerge 0.056 (0.654) 
Rpim 0.023 (0.266) 
CC(1/2) 0.999 (0.834) 
Mean of I/σI 19.2 (2.6) 
Completeness 100.0 (99.9) 
Multiplicity 7.0 (7.0) 
Wilson B factor (Ang2) 60.19  
3.2.4 Solving the CysK structure 
Various CysK homologues present in the PDB were selected to be potential candidates 
for molecular replacement with good sequence similarity (≥ 30%) and conservation of 
secondary structural features (Figure 3.9). Based on this information, the M. tuberculosis 
CysK structure (3ZEI) (Poyraz et al., 2013) was chosen as the search model for molecular 
replacement as it exceeded the minimum requirements of sequence similarity (57%) and 









Figure 3.9: ENDscript analysis of the secondary structure of CysK from N. gonorrhoeae. For each residue solvent accessibility (acc) and hydrophobicity (hyd) are labelled 
below the sequence. acc is rated as blue being accessible, cyan less accessible, and white being completely buried from solvent (red being not calculated). hyd is ranked as cyan 
being hydrophilic, purple being hydrophobic and white being neutral. Secondary structure elements are labelled in grey above the peptide sequence, with helices, β-strands, and 
β-turns, represented by linked loops, arrows and TT, respectively. Letters indicate noncrystallographic interaction with chain denoted by letter. Refer to (Appendix D.1 Contents 













The Matthew’s coefficient was used to predict the number of monomers in the 
asymmetric unit (ASU) (Matthews, 1968). The most likely number of monomer copies 
present was determined to be four, calculated with a predicted molecular weight of 32.726 
kDa for CysK from Protparam as per section 2.4.5. Thus, the CysK monomer (3ZEI) was 
used as a search model for molecular replacement with four monomers in the ASU 
(phenix.phaser). Phaser found a solution with good TFZ and LLG scores of 19.6 and 
687.620, respectively (McCoy et al., 2007).  
 
The CysK model was built using the autobuild.phenix programme. The programme was 
supplied with the phenix.phaser output model and map, reflection file (with FreeR flag 
dataset) and the CysK amino acid sequence. Initially, default settings were used 
(Appendix D.2 Initial input settings for phenix.autobuild), except waters were not placed 
in the refinement. The building reached a threshold where the Rfree and Rmerge values were 
not improving. Therefore, default settings with minor alterations were used for the final 
rounds of structure building, where waters were not placed in the refinement, and rebuild 
in place was set to false (Appendix D.3 Final input settings for phenix.autobuild). The 
latter step allows the programme to edit the structure file based on the sequence file, as 
well as build outside the model (if there is unmodelled density present). The structure 
went through six iterative building rounds and three cycles of refinement. The resulting 
structure had a good Rwork/Rfree score for a starting model of 0.2305/0.3060. In the 
asymmetric unit, 4 monomers were built, with two forming a homodimer, while the two 
remaining monomers were positioned either side of the homodimer. The majority of each 
monomer was built by automated building using phenix.autobuild, however, there were 
large sections of the protein’s amino acid sequence missing. The sections missing from 
Pro-137-Asn-151 and Glu-204-Ser-240 in each monomer were manually built in COOT.  
3.2.5 Analysis of the CysK structure  
The final structure model for CysK has a Rwork/Rfree of 0.2099/0.2623 (Table 3.8). 
Structure and map files for the CysK model are listed in (Appendix D.4 CysK structural 
files). There was no density to support the C-terminal tail from Leu-297 onwards 
including the hexahistidine-tag in any of the chains within the ASU, or the first two 
residues of each monomer. There was also no density to support Pro-143-Asn-151 or 
Glu-204-Tyr-238 (± 2 residues in some chains) across all four monomers in the ASU. 
The overall structure of CysK is moderately well built, with an average monomer length 
of 254.5 residues (254.5/312, 81.6% built) (Appendix D.5 CysK chain statistics).  
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The CysK monomer consists of an N-terminal domain spanning residues Val43-Pro143 
and a C-terminal domain spanning residues Ile11-Ser42 and Asn151-Tyr296. The 
N-terminal domain is potentially extended further than residue Pro143, however, due to 
resolution restrictions and the potential flexibility of this region, there is a gap in the 
structure from Arg144-Ala150. The C-terminal domain also has a gap in the residue 
sequence from Glu204-Ile229, and the C-terminal tail extends further beyond Tyr296, 
however, due to both resolution and the flexibility of the C-terminal tail, these are the 
limits of the C-terminal domain.  
Table 3.8: CysK final model quality statistics. Statistics generated by phenix.tableone. 
 
Data statistic  CysK 
Rwork 0.2099 
Rfree 0.2623 
No. of protein residues 1038 











Average B value (Å) 64.25 
Macromolecules 64.18 
Solvent 66.08 
Ramachandran analysis  
No. of residues in favoured region 
(%) 
97.33 
No. of residues in allowed region (%) 2.38 
No. of residues in outlier region (%) 0.30 






Figure 3.10: Structure of the CysK monomer from N. gonorrhoeae. N and C terminal domains outlined on 
the figure. Each domain is coloured from the N-terminus (blue) to the C-terminus (red). Helices are labelled 
with α. β-sheets are labelled with β. Figure generated in PyMOL. 
3.2.5.1 Analysis of the CysK dimer  
The CysK dimer has a height of 46.2 Å, and a width of 61.7 Å and has two-fold symmetry. 
The monomer-monomer formation of the dimer is a result of multiple hydrogen bonds 
and hydrophobic interactions between the monomers. A small portion of the dimer 
surface area is buried at the monomer-monomer interface, with 2840 Å2 of a total dimeric 
surface area of 22230 Å2 (12.8%) (calculated as per section 2.12.4). The calculated free 
energy for the dissociation (ΔGdiss) of the dimer is 10.7 kcal.mol-1, demonstrating that the 
dimeric arrangement is thermodynamically stable. CysK has been confirmed to elute as 
a dimer by gel filtration chromatography (Figure 3.2). 
3.2.5.2 Analysis of the CysK N-terminal domain 
The N-terminal domain consists of a central three-stranded parallel β-sheet which is 
flanked by three α-helices on one side and a single α-helix on the other side (Figure 3.9, 
Figure 3.10 and Figure 3.11). Tyr-140 and Phe-141 are indicated to be the beginning of 























Arg144-Ala150, this cannot be determined in this structure. The domain begins with an 
α-helix (α1, Val43-Ala58), and a meandering loop (Gly59-Val66) links to the first central 
β-sheet (β3, Ile67-Thr71). A sharp turn (Ser72-Gly73) links to the second α-helix (α2, 
Asn74-Arg86). The second β-sheet begins (β4, Lys90-Pro95), running parallel to β3 after 
a sharp turn (Gly87-Lys89). From β4 to α3 (Lys100-Phe109) there is a sharp turn 
(Glu96-Ser99). From α3 there is another sharp turn (Gly110-Ala111) to the third of the 
central parallel β-sheets (β5, Glu112-Thr116). A single residue sharp turn (Pro-117) leads 
to the α-helix on the other side of the central parallel β-sheets (α4, Ala118-Ala135). From 
here, a meandering loop (His136-Thr139) looks to be linking to a fourth central parallel 
β-sheet that is suggested to begin at Tyr-140 (STRIDE, (Frishman & Argos, 1995)). The 
linkage between the N-terminus and the C-terminus is missing as one of the residue gaps 
(Arg144-Ala150). The C-terminal domain begins at Asn151, however, there is also a 
small section of the C-terminal domain from residues Ile11-Ser42. 
 
 
Figure 3.11: Structure of the CysK N-terminal domain from N. gonorrhoeae. Helices are coloured red and 
labelled with α. β-sheets are coloured yellow and labelled with β. Loops and turns are coloured green. 
Figure generated in PyMOL. 
3.2.5.3 Analysis of the CysK C-terminal domain 
The C-terminal domain consists of a central six-stranded mixed β-sheet with two 
α-helices on either side (Figure 3.9, Figure 3.10 and Figure 3.12). The domain begins 
with a loop (Ile11-Pro15) to the first β-sheet (β1, Leu16-Lys18) and continues with a 
meandering loop (Leu19-Ala28) to the second central β-sheet (β2, Glu29-Leu34). There 































Figure 3.12: Structure of the CysK C-terminal domain from N. gonorrhoeae. Helices are coloured red and 
labelled with α. β-sheets are coloured yellow and labelled with β. Loops and turns are coloured green. 
Figure generated in PyMOL. 
 
The C-terminal domain continues from Asn151, and the first α-helix of the domain begins 
(α5, Pro152-Thr167). A loop (Asp168-Asp172) links to the third central β-sheet (β6, 
Val173-Gly177). The second α-helix (α6, Thr183-Tyr194) is linked to β6 by a short loop 
(Val178-Gly182) which includes the majority of the PLP interacting 179-GTGGT-183 
motif. A turn (Lys195-Ile198) continues from α6 to the fourth central β-sheet (β7, 
Glu199-Val203) where the residue sequence ends at the Glu204-Ile229 gap. The 
C-terminal domain continues with a meandering loop (Pro230-Asp239) to the fifth central 
β-sheet (β8, Ser240-Ala242). A tight turn (Lys243-Pro245) links to the domains third α-
helix (α7, Asn246-Glu260), which links to the domains fourth α-helix (α8, Ile266-Lys280) 
via a turn (Gly261-Gly265). A meandering loop (Gln281-Gly286) connects to the final 
β-sheet of the domain (β9, Lys287-Leu293), after which the C-terminal domain ends with 
a loop (Pro294-Tyr296). The C-terminal tail is missing 16 residues in this structure, 
however, this is consistently found across CysK structures in the PDB (Salsi et al., 2010; 
Poyraz et al., 2013), and is most likely a result of the C-terminal tail’s flexibility.   
3.2.5.4 Structure of the CysK active site  
The functional enzyme forms a homodimer of ~75.452 kDa and characteristic of the Fold 
type II family, the active site of the enzyme is made up of residues all from one subunit 
(Liang et al., 2019). Alignment of the CysK protein sequence from N. gonorrhoeae with 
other bacterial homologues, demonstrates moderate sequence similarity compared to 
other proteobacterial and plant species (average 54.20% sequence similarity), but shows 
strong conservation of the PLP co-factor interacting residues Lys-44, Val-40, Ser-266, 
the asparagine loop at Asn-74, the substrate carboxylate binding Gln-145 and the PLP 






















residues 71-TSGNTG-76 (Joshi et al., 2019) (except the moderately conserved Serine) 
and 223-GIGA-226 (Joshi et al., 2019) are also strongly conserved in the six species 
across the ranges 68/72-72/76 and 222/228-225/231, respectively (Figure 3.13). The 
closest structural relatives of N. gonorrhoeae CysK are from M. tuberculosis (Poyraz et 
al., 2013) and H. influenzae (Salsi et al., 2010) with root mean square deviation values 
after  
Figure 3.13: CysK protein sequence alignment. The N. gonorrhoeae FA1090 CysK amino acid sequence 
was aligned to the following CysK homologues; M. tuberculosis (65.7% sequence similarity); S. 
typhimurium (55.05% sequence similarity); H. influenzae (55.84% sequence similarity); A. thaliana (55.02% 
sequence similarity) and B abortus (39.41% sequence similarity). Highly conserved residues are 
highlighted in red, whilst less conserved residues are highlighted in yellow. Sequence alignment created 





































Figure 3.14: Structural overlay of N. gonorrhoeae and M. tuberculosis CysK monomers. (a) active site and 
PLP interacting residues shown in licorice-stick format. (b) active site and PLP interacting residues shown 
as the surface of the active site cleft. N. gonorrhoeae structure shown in green. M. tuberculosis structure 
shown in cyan. PLP shown in orange. AWH (3-((Z)-((Z)-5-(4-Fluorobenzylidene)-3-methyl-4-
oxothiazolidin-2-ylidene) amino) benzoic Acid) shown in magenta. Red sections of the surface of the active 
site cleft indicate negative potential. Blue sections of the surface of the active site cleft indicate positive 






structural superposition of 1.1 Å (229 equivalent C-atoms) and 1.274 Å (219 equivalent 
C-atoms), respectively. The active site residues 71-TSGNTG-76 and 223-GIGA-226 are 
strongly conserved in N. gonorrhoeae and have been identified through sequence 
alignment (Figure 3.13). However, as a function of resolution constraints and the 
flexibility of the loop, residues 223-GIGA-226 are not visible in the CysK structure. 
Alignment of the N. gonorrhoeae and M. tuberculosis CysK structures indicate the 
71-TSGNTG-76 active site residues from N. gonorrhoeae have the same conformation 












Figure 3.15: Alignment of N. gonorrhoeae and M. tuberculosis CysK active site and PLP interacting 
residues, in licorice-stick format. Active site residues 71-TSGNTG-76 and PLP interacting residues; Val-43, 
Lys-44, Asn-74, Ser-267 and 179-GTGGT-183 motif from N. gonorrhoeae are labelled. M. tuberculosis 
active site residues 223-GIGA-226 on the right are not labelled. N. gonorrhoeae monomer D residues 
shown in green. M. tuberculosis residues shown in cyan. PLP shown in orange. AWH (3-((Z)-((Z)-5-(4-
Fluorobenzylidene)-3-methyl-4-oxothiazolidin-2-ylidene) amino) benzoic Acid) shown in magenta. Figure 
generated in PyMOL. 
 
Overall, the active site residues and PLP interacting residues that form the active site cleft 
align in a very similar conformation in N. gonorrhoeae and M. tuberculosis structures 
(Figure 3.14, Figure 3.15 and Figure 3.16). Despite the absence of the 223-GIGA-226 
active site residues from the N. gonorrhoeae CysK structure (Figure 3.15), it is clear the 
structures form a very similar active site cleft. The binding of AWH (3-((Z)-((Z)-5-(4-
Fluorobenzylidene)-3-methyl-4-oxothiazolidin-2-ylidene) amino) benzoic Acid) into the 
M. tuberculosis active site gives a good indication of how O-acetylserine would bind into 
the active site of CysK in N. gonorrhoeae. AWH is a novel thiazolidine inhibitor of OASS, 





























Figure 3.16: CysK active site cleft formed by the active site (71-TSGNTG-76 and 223-GIGA-226) and 
PLP interacting (Val-43, Lys-44, Asn-74, Ser-267 and 179-GTGGT-183 motif) residues from 
M. tuberculosis (a) and N. gonorrhoeae (b). PLP shown in orange. Note the region missing in the 
N. gonorrhoeae structure in (b) corresponds to the missing GIGA flexible loop in the active site. Figure 
generated in PyMOL. 
 
Structural alignment of the M. tuberculosis OASS-A/CysK enzyme with our isolated 
OASS isoform from N. gonorrhoeae indicates, our enzyme is also an OASS-A/CysK 
enzyme rather than the alternate isoform OASS-B/CysM which has a larger active site. 
Due to the strong structural similarity between N. gonorrhoeae and M. tuberculosis CysK 
enzymes (Figure 3.14, Figure 3.15 and Figure 3.16), it is assumed that the overall surface 
structure between the two enzymes will be the same if the N. gonorrhoeae structure was 
not missing active site residues (223-GIGA-226) and Glu204-Pro230 stretch. Therefore, 
to confirm the OASS enzyme from N. gonorrhoeae is a true OASS-A/CysK isoform, we 
compared the structure of M. tuberculosis CysK (3ZEI (Poyraz et al., 2013)) with the 








Figure 3.17: CysK and CysM monomers from M. tuberculosis, E. coli and N. gonorrhoeae focused on the 
active site cleft. (a) CysK from M. tuberculosis. (b) CysM from E. coli. (c) CysK from N. gonorrhoeae. 
Active site cleft forming residues are shown in grey. PLP shown in orange. 
 
The active site residue loop (Arg211-Asp227) from CysM extends further than the active 
site in CysK (Figure 3.17) showing a larger active site capable of accommodating the 
larger thiosulphate molecule compared to the smaller active site seen in CysK only 
capable of accommodating sulphide. This is largely due to the three residues found at the 
beginning of the CysM active site loop, Arg210, Arg211, and Trp212, whereas CysK has 
significantly smaller residues at a similar position, Lys210, Ser211, and Gly212 (Claus et 
al., 2005). The N. gonorrhoeae CysK is missing a large section of its active site cleft due 
to the Glu204-Pro230 stretch absent from the structure as a function of resolution and 
flexibility of this loop.  
3.2.5.5 Interaction of the CysK active site with PLP 
The heavily conserved PLP interacting residues Val-43, Lys-44, Asn-74, Ser-267 and the 
179-GTGGT-183 motif are present within the CysK crystal structure, however, although 
co-purified with PLP there is no density to support PLP bound in the active site. 
Interactions with PLP are assumed to be highly conserved across CysK enzymes from 
many organisms as these residues are highly conserved (Figure 3.13). In M. tuberculosis, 
the 3-hydroxyl group of PLP hydrogen bonds to the side chain of Asn-74 within the highly 
conserved sequence Glu69-Gly76. This highly conserved sequence is present in 
N. gonorrhoeae from Thr71-Gly76 (Figure 3.13) and so should share the same interaction. 
Ser-267 which hydrogen bonds to PLP’s pyridine nitrogen in S. typhimurium (Rabeh & 
Cook, 2004) is also highly conserved. Many related OASS-A enzymes show essentially 
(a) (b) (c) 
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the same interactions with the PLP cofactor (Schnell et al., 2007), so we assume this will 
be the same in N. gonorrhoeae. 
The PLP interacting residues from each monomer of the dimer seen in the ASU 
(Monomer A and D, Appendix D.2) were overlaid with the corresponding residues from 
the M. tuberculosis CysK structure (Figure 3.18 and Figure 3.19) to investigate active site 
architecture.  
 
Figure 3.18: Aligned PLP interacting residues from N. gonorrhoeae monomer A and M. tuberculosis CysK 
monomer with PLP present, in licorice-stick format. This is monomer A from the ASU (Appendix D.2). 
N. gonorrhoeae CysK is shown in green. M. tuberculosis CysK is shown in cyan. PLP is shown in orange. 




Figure 3.19: Aligned PLP interacting residues from N. gonorrhoeae monomer D and M. tuberculosis CysK 
monomer with PLP present, in licorice-stick format. This is monomer D from the ASU (Appendix D.2). 
N. gonorrhoeae CysK is shown in yellow. M. tuberculosis CysK is shown in cyan. PLP is shown in orange. 
N. gonorrhoeae residues are labelled. Right diagram is the left diagram rotated 90º. Figure generated in 
PYMOL. 
 
The 179-GTGGT-183 motif in monomer A is blocking the PLP binding site and is in a 
significantly different conformation to the same motif in the M. tuberculosis CysK 









































conformation as CysK is PLP dependent and it is unable to bind with the PLP interacting 
residues here. Conversely, in monomer D, this same motif is in a different conformation 
that is not preventing binding of the PLP co-factor (Figure 3.19). The Thr-178 sidechain 
appears particularly close to the phosphate of the PLP. However, considering the slightly 
different conformation of Lys-43, Gly-179, Thr-180 and the different relative positions 
of the PLP interacting residues there is still room for the PLP co-factor to bind as this 
PLP molecule is aligned to the M. tuberculosis PLP interacting residues. This indicates 
monomer D is in an active conformation. To confirm monomer A is correct in the 
structure, the residue map was checked in WINCOOT, indicating there is no density 
supporting the 179-GTGGT-183 motif in the same conformation as monomer D (active 




Figure 3.20: Monomer A electron density residue map with 179-GTGGT-183 motif in the same 
conformation as monomer D. Oxygen is shown in red. Nitrogen is shown in blue. Carbon is shown in 
yellow. Figure generated in WINCOOT. 2Fo-Fc and Fo-Fc map contoured at one and three σ, respectively. 
 
This indicates our structure of the N. gonorrhoeae CysK dimer has one monomer in an 
active conformation and the other in an inactive conformation.    
3.2.5.6 N. gonorrhoeae CysK structure conclusions and future directions 
N. gonorrhoeae CysK has all of the highly conserved PLP interacting (Val-43, Lys-44, 
Asn-74, Ser-267, 179-GTGGT-183 motif) and active site (71-TSGNTG-76 and 
223-GIGA-226) residues, all of which form the active site cleft.  
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Interestingly, in the N. gonorrhoeae CysK structure we see two different conformations 
of the PLP interacting loop motif 179-GTGGT-183 in adjacent monomers in the dimer. 
In monomer A the conformation blocks PLP from being able to bind, and in monomer D 
is an active form, capable of PLP binding. The other monomer, however, was in an 
alternate conformation that accommodated the binding of PLP. Therefore, it was 
surmised that one monomer within the N. gonorrhoeae CysK dimer is in an inactive 
conformation whilst the other is in an active conformation.  
 
Comparison of the active site cleft also supports the conclusion that this OASS isoform 
is the OASS-A/CysK isoform. However, due to the residues missing from the crystal 
structure (Glu204-Pro230), which also contain the active site residues 223-GIGA-226, 
this comparison between the CysM (E. coli) and CysK (M. tuberculosis) active site clefts 
cannot conclusively state our OASS is CysK. However, this combined with the structural 
similarity between M. tuberculosis CysK and N. gonorrhoeae OASS, allows us to 
conclude we have isolated OASS-A, a CysK isoform from N. gonorrhoeae. 
 
As a result of comparing the active site cleft from CysK (M. tuberculosis) with CysM 
(E. coli), a higher resolution structure is required to conclusively state our enzyme is the 
OASS-A/CysK isoform by structural comparison of the active site to a OASS-B/CysM 
isoform active site. Future research will also involve co-crystallisation of our CysK with 
substrates OAS and Na2S in the active site to allow determination of the interactions 
between monomers and their active site conformations. Crystallisation in the presence of 
chloride could also elucidate the potential presence of an allosteric anion binding site 









3.3 Investigating Cysteine Synthase Complex formation in 
N. gonorrhoeae 
3.3.1 The Cysteine Synthase Complex 
The cysteine synthase bienzyme complex was first discovered during purification of 
CysE and CysK from S. typhimurium (Kredich & Tomkins, 1966; Kredich et al., 1969). 
Complex formation has since been confirmed across many other species including E. coli 
(Mino et al., 2000; Benoni et al., 2017b), H. influenzae (Salsi et al., 2010) and various 
plant species (Yi et al., 2013). The CSC is an unusual protein complex, as most form to 
shuttle substrates/products from one enzyme to another. The CSC is different as it forms 
via binding of the CysE C-terminal tetrapeptide into the active site of CysK, halting all 
CysK activity and thus, cysteine production (Kredich et al., 1969; Mino et al., 2000; Salsi 
et al., 2010; Yi et al., 2013; Benoni et al., 2017b; Hicks & Mullholland, 2018). One 
hypothesis for the formation of the CSC is for modulation of sulphur flux within bacterial 
metabolism (Hell & Wirtz, 2002; Wirtz et al., 2012). The key residues required for 
binding of the CysE tail to the CysK active site were determined via screening a 
tetrapeptide library for binding ability, which was monitored by CysK activity and PLP 
fluorescence (Campanini et al., 2005). It was established that a C-terminal isoleucine is 
both essential for binding and inhibition of CysK and is well-conserved across CSC 
forming organisms (Campanini et al., 2005; Huang et al., 2005; Salsi et al., 2010; Benoni 
et al., 2017b). The C-terminal tetrapeptide sequence in N. gonorrhoeae CysE was 
confirmed to have the conserved isoleucine with a four-residue sequence DFMI (Oldham, 
2020), therefore it was predicted that CysK and CysE from N. gonorrhoeae are able to 
form the CSC. Formation of this complex has not yet been characterised in 
N. gonorrhoeae.  
3.3.2 Monitoring CSC formation by fluorescent spectroscopy 
Evaluation of CSC formation has been successful in studies by (Kumar et al., 2011), 
(Campanini et al., 2005) and (Wang & Leyh, 2012). This is a result of measuring the 
fluctuations in fluorescence linked to the binding of the CysE tail into the CysK active 
site and alternate conformations of the co-factor, PLP. Within CysK, the co-factor PLP is 
covalently attached to a conserved Lysine in the active site (Lys-44 in N. gonorrhoeae 
CysK) which forms a fluorescent protonated internal aldimine (Figure 1.9) (Wang & 
Leyh, 2012). This protonated internal aldimine has two tautomers, the ketoenamine and 
the enolimine, which each have distinct fluorescent spectral features. The ketoenamine 
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has an excitation wavelength of ~414 nm with an emission spectrum of ~510 nm which 
changes upon partial closure of the CysK active site (Wang & Leyh, 2012). Within the 
CysK active site, binding at a subsite that binds the α-carboxyl of substrates causes partial 
closing of the CysK active site. This closure is proposed to cause the observed ~15 nm 
blue shift in PLP emission spectra due to a lengthening of the ketoenamine excited-state 
lifetime (Wang & Leyh, 2012). The C-terminal carboxylate of CysE C-terminal peptides 
has been shown to bind to the CysK acceptor subsite, causing the same ~15 nm blue shift 
that substrate binding to the CysK subsite causes. Thus, indicating the CSC formation can 
be monitored by the ~15 nm blue shift as a result of the change in PLP fluorescence 
caused by binding of the CysE C-terminal tail or tetrapeptide into the CysK active site.  
3.3.3 Binding of CysE to CysK to form the CSC 
CysK and CysE were freshly purified by IMAC and gel filtration as per sections 2.4 and 
2.13.1, respectively, using the previously described buffer for CysE and a modified buffer 
for CysK (pH 8.0 rather than 7.0). Both proteins were purified individually for use in CSC 
formation experiments.   
 
Initially, the two freshly purified enzymes were combined in a quartz cuvette in a 4:1, 
CysK:CysE molar ratio and mixed manually using a stir rod. This manual mixing resulted 
in visible protein precipitation. To prevent protein precipitation after addition of CysE, 
the emission wavelength was measured at addition of CysE without manual mixing 
(0 min), and two minutes after to allow mixing to occur. Combination of the two enzymes 
for CSC formation experiments was conducted as per section 2.13.2.2.  
 
CysK and CysE were combined at a variety of molar ratios and emission wavelength 





























Figure 3.21: Fluorescent spectroscopy emission wavelength scans of CysK:CysE ratios for CSC formation. 
CysK:CysE (a) 4:1 (b) 2:1 (c) 1:1 (d) 2:3 (e) 1:2 (f) CysK only scan. Measured at room temperature 22 ºC. 
Excitation wavelength 400nm. Emission wavelength measured between 450-600nm. 
 
Table 3.9: Fluorescent spectroscopy emission wavelength measurements of the CysK:CysE ratio for CSC 
formation. Wavelength of the apex of each peak for each reaction condition are recorded. CysK and CysE 




Peak Apex measurements (nm) 
0 (min) 2 (min) 
4:1 498 495 
2:1 464.2 
- 
Peak 1: 464.8 
Peak 2: 497 
1:1 Peak 1: 464 
Peak 2: 516.6 
Peak 1: 464.8 
Peak 2: 498.6 
2:3 464 464.2 
1:2 463.8 463.4 
CysK only  497.6 - 
 
Data processing identified the number of peaks and their corresponding apex wavelength 
(Table 3.9). The wavelengths in Table 3.9 indicate an approximately 35 nm blueshift in 






However, visual interrogation of the spectra (Figure 3.21) shows this supposed blueshift 
peak at approximately 465nm is present in all spectra at all CysK:CysE ratios. The 
emission peak at approximately 500nm is also present in all spectra (Figure 3.21). 
Interestingly, despite the CysK concentration remaining constant, the peak seen at 
approximately 500nm decreases in intensity as the ratio of CysK:CysE decreases (Table 
3.10). The 465nm peak also decreases in intensity until the 1:1, CysK:CysE ratio (Table 
3.10). 
Table 3.10: Changes in fluorescence peak intensity over varied CysK:CysE ratios. Both 500nm and 465nm 
peak are shown. 
 
CysK:CysE ratio 500nm Peak 465nm Peak 
 0 min 2 min 0 min 2 min 
4:1 11.43 10.81 10.11 9.862 
2:1 8.489 8.917 8.757 8.963 
1:1 7.997 8.318 8.139 8.410 
2:3 6.842 7.191 8.063 8.184 
1:2 6.689 6.450 7.917 7.967 
 
As the peak seen at 465nm is not present in the solely CysK fluorescent scan (Figure 3.21f), 
it is assumed this peak is due to the addition of the CysE protein. However, further 
fluorescent wavelength scans of solely CysE need to be conducted to confirm this.  
 
The absence of a peak at 485 nm indicates no 15 nm blueshift in the fluorescence spectra, 
thus, showing the CSC has not formed in this experiment. A possible explanation for the 
CSC not forming, is the presence of O-acetylserine (OAS), which is able to dissociate the 
complex at OAS concentrations upwards of 50 µM (Kredich et al., 1969; Wang & Leyh, 
2012; Benoni et al., 2017a). OAS is a common metabolite present in E. coli (Sajed et al., 
2016), thus, making it possible that OAS from E. coli expression strain BL21 (DE3) could 
co-purify with CysK or CysE, therefore preventing CSC formation. However, OAS is 
unstable at pH values greater than 7.6 (Kredich & Tomkins, 1966), where it will 
non-enzymatically and rapidly convert to N-acetylserine, which is unable to bind to CysK 
(Kredich & Tomkins, 1966). Given CysK purification for this experiment was conducted 
at room temperature in potassium phosphate buffers with a constant pH of 8.0, there was 
likely little to no O-acetylserine present, and can therefore be ruled out as the cause of the 
CSC not forming.  
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3.3.4 Binding of a CysE C-terminal tetrapeptide to CysK 
A four amino acid peptide corresponding to the last four amino acids of the CysE 
C terminal tail was synthesised with the sequence DFMI to test for binding to CysK. A 
four amino acid peptide was chosen as in previous studies this was shown to bind to the 
enzyme and inhibit activity (Salsi et al., 2010; Kumar et al., 2011).  
 
CysK and the tetrapeptide were freshly thawed for use in fluorescence spectroscopy and 
experiments were conducted as per section 2.13.2.3. CysK and the tetrapeptide were 
combined at a variety of molar ratios and emission wavelength scans from 450-600nm 
were carried out at an excitation wavelength of 386.2nm (Figure 3.22). The excitation 
wavelength for these CysK:CysE tetrapeptide fluorescent wavelength scan experiments 
differ from the CysK:CysE protein fluorescent wavelength scan experiments above as the 
preliminary excitation wavelength scan completed as per section 2.13.2.3 indicated a 
different excitation wavelength (386.2nm). All measurements were conducted whilst 
mixing with a magnetic stirrer, and no precipitation was observed. Processed data 
indicated the number of peaks and their corresponding apex wavelength (Table 3.11). 
These apex wavelengths indicate an initial redshift (~30 nm) from the initial emission 
wavelength measured (471 nm) in the 4:1, CysK:CysE tetrapeptide mixture. All other 
CysK:CysE tetrapeptide ratios indicate essentially no change in wavelength as they 
fluctuate within the 490-500 nm range in a seemingly random pattern. Interestingly, 
despite the CysK concentration remaining constant, visual interrogation of the fluorescent 
spectra (Figure 3.22) indicate the intensity of the peaks in the 490-500nm range increases 
as the CysK:peptide ratio decreases (Table 3.12). 
 
The absence of a 15 nm blueshift in the fluorescence spectra indicates there has been no 
binding of the tetrapeptide to CysK, therefore partial closure of the CysK active site has 
not occurred and, no change in PLP fluorescence has occurred. Thus, further indicating 
the CSC does not from in N. gonorrhoeae. In this experiment, the presence of OAS due 
to carryover during expression in E. coli may be possible.  CysK used in this experiment 
was purified in potassium phosphate buffers at pH 7.0 at which, OAS is more stable and 
does not rapidly convert to NAS (Kredich & Tomkins, 1966). Thus, OAS may have been 
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present in the thawed CysK aliquot at concentrations above 50 µM causing dissociation 
of any CysE C-terminus tail peptide that may have bound to the CysK active site.  
Figure 3.22: Fluorescent spectroscopy emission wavelength scans of CysK:CysE C-terminus tetrapeptide 
ratios for CSC formation. CysK: CysE C-terminus tetrapeptide (a) 4:1 (b) 2:1 (c) 1:1 (d) 1:2 (e) 1:3 (f) 1:4 
(g) 1:5 (h) CysK only. Measured at room temperature 22 ºC. Excitation wavelength 386.2nm. Emission 






















Table 3.11: Fluorescent spectroscopy emission wavelength measurements of CysK binding to the CysE 
tetrapeptide. Wavelength of the apex of each peak for each reaction condition are recorded. CysK and CysE 
C-terminus tetrapeptide were freshly thawed. Measurements were taken at room temperature 22 ºC. 
Excitation wavelength 386.2nm. Emission wavelength measured in the 450-600nm range.  
 
CysK:CysE C-terminus tail peptide monomeric 
ratio 
Peak Apex measurements (nm) 
0 (mins) 2 (mins) 
4:1 499 498 
2:1 497.8 494.8 
1:1 494.8 493.6 
1:2 500.4 493 
1:3 495.2 498.8 
1:4 490.2 494.4 
1:5 494 495.6 
CysK only 471 - 
 
The change in the excitation wavelength for the PLP cofactor between the CysE-CysK 
and tetrapeptide-CysK experiments (400nm vs 386.2nm) is unexpected and cannot be 
explained. There are three factors that differ between the CysK:CysE and CysK:CysE 
C terminus tetrapeptide fluorescence experiments; (1) 25% (v/v) glycerol was present in 
the peptide experiments, due to carryover from freezing CysK in glycerol (2) the CysK 
and CysE C-terminus tetrapeptide are in potassium buffers at pH 7.0 rather than pH 8.0 
for the CysK:CysE experiment and CysE protein was in Tris buffer, and (3) the CysE 
C terminus tetrapeptide is present rather than the whole CysE enzyme. Despite these 
factors, the change in excitation and emission wavelength cannot be explained.  
Table 3.12: Changes in fluorescence peak intensity over varied CysK:CysE tetrapeptide ratios. 490-500nm 
peak is shown. 
 
CysK:CysE tetrapeptide ratio 490-500nm Peak 
 0 mins 2 mins 
4:1 18.41 18.58 
2:1 18.96 18.89 
1:1 18.89 18.68 
1:2 19.63 19.57 
1:3 20.67 20.48 
1:4 20.76 20.59 
1:5 20.95 21.00 
 
Both CysK:CysE and CysK:CysE C-terminal tetrapeptide fluorescence spectroscopy 
experiments show no formation of the CSC occurring, as no 15 nm blue shift caused by 
 
81 
the partial closing of the CysK active site resulting in a change in the PLP fluorescence 
occured. However, CSC formation has previously been confirmed in other organisms via 
gel filtration chromatography (Kredich et al., 1969; Kumaran et al., 2009), so we tested 
the ability of CysE and CysK from N. gonorrhoeae to form the CSC by gel filtration 
chromatography.  
3.3.5 Monitoring CSC formation by gel filtration chromatography 
Formation of the CSC was also investigated by gel filtration chromatography using 
freshly purified CysK and CysE as per sections 2.4 and 2.13.1, respectively, using the 
same buffers as previously mentioned for CysE and modified buffers for CysK (pH 8.0 
rather than 7.0). Both proteins were purified individually for use in CSC formation 
experiments, and analysed using a calibrated gel filtration column. CysE elutes from an 
Enrich 650 analytical gel filtration column (BioRad) at 12.28 ml, corresponding to a 
molecular weight of 193.8 kDa, consistent with a CysE hexamer (Figure 3.23a) (Oldham, 
2020). CysK elutes at 14.6 ml, corresponding to a molecular weight of 52.862 kDa, 
consistent with a dimer (Figure 3.23b), which is in keeping with section 3.1.2. CysK and 
CysE proteins purified in the expected multimeric forms of a dimer and a hexamer, 




Figure 3.23: Monitoring formation of the CSC by gel filtration chromatography. Elution profiles of CysE 
(a), CysK (b) and CysE:CysK at molar ratios of 3:2 (c) and 1:1 (d) shown. All peaks are labelled with 
elution volumes. The absorbance values for the 1:1 ratio are negative as the buffer background was not set 
to zero after previous use.  
 
To monitor formation of the CSC, CysE and CysK were mixed at a 3:2 and 1:1 molar 
ratios and analysed by gel filtration chromatography (section 2.13.2.1).  
 
If CysE and CysK formed the CSC we would expect to see an earlier elution peak 
compared to the CysE and CysK proteins only. A homologous CSC from E. coli indicates 
the CSC is composed of one hexamer and two CysK dimers (3:2 molar ratio) (Benoni et 
al., 2017b). For N. gonorrhoeae this would form a CSC with a predicted molecular weight 
of ~332 kDa, corresponding to an elution volume of 11.9 ml which is not seen in either 
Figure 3.12c or Figure 3.12d, indicating the CSC had not formed.  
 
The lack of elution peaks corresponding to the CSC indicates there is no formation of the 







CysK, respectively. The peak observed at 12.5 ml and 14.14 mL (Figure 3.23d), also 
correspond to individual CysE and CysK proteins respectively.  
3.3.6 CysK peptide inhibition assays 
Given the apparent inability of CysE and CysK to form the CSC, and the inability of the 
four amino acid CysE C-terminal tetrapeptide to bind to CysK, we investigated if the 
CysE tetrapeptide could inhibit enzyme activity, which would indicate binding to the 
enzyme. Tetrapeptide inhibition assays were conducted with the four amino acid peptide 
that mimics the last four amino acids of the C-terminal tail of CysE. If the tetrapeptide 
binds into the CysK active site, inhibition of enzyme activity should occur, thus allowing 
activity assays to indicate potential CSC formation. Assays were set up as per section 2.8. 
A variety of tetrapeptide concentrations (0.0764, 0.1528, 0.2292, 0.3056, 0.764, 1.528, 
7.64, 15.28, 22.92, 30.56, 114.6 and 191 pmol) were trialled in an attempt to collect an 
IC50 curve for peptide inhibition (1.632 µg CysK = 49.75 pmol of CysK monomer) 
(Figure 3.24).  
 
 
Figure 3.24: Activity of CysK in the presence of the CysE tetrapeptide. Split scale with 30% of the scale 
showing 0.0764-1.528 pmol varied peptide conditions. Right 70% of the scale portrays activity of 7.64-191 
pmol varied peptide conditions. OAS concentration constant at 1 mM. Na2S concentration constant at 7 
mM. All assays were conducted with 49.75 pmol of CysK monomer at 37 ºC with freshly thawed CysK. 
All reaction conditions were collected in duplicate. Error bars represent standard error.  
 
Figure 3.24 indicates a large variance in activity at varied peptide concentrations, making 
the fitting of a kinetic model particularly difficult. An accurate IC50 curve was not 
obtained and, given the large error bars, kinetic parameters of an IC50 curve cannot be 




(at peptide concentrations 22.92 and 30.56 pmol) are within the maximum rates observed 
in reactions with no tetrapeptide present. This indicates the CysE tetrapeptide does not 
bind to CysK and inhibit its activity. The OAS concentration was held at 1 mM 
(1 mM = 1000 µM) in these assays to mitigate the dissociation effect OAS may have on 
the tetrapeptide binding into the CysK active site. However, dissociation of the CSC can 
occur at µM concentrations of OAS (upwards of 50 µM OAS) (Kredich et al., 1969; 
Wang & Leyh, 2012; Benoni et al., 2017a). Therefore, the lack of inhibition seen in these 
assays may be a result of the presence of dissociating concentrations of OAS, thus, 
dissociating any tetrapeptide that may have bound to the CysK active site, making it 
difficult to draw any certain conclusions from these assays.  
3.3.7 CSC formation conclusions and future directions 
The CysE C-terminus tetrapeptide did not cause inhibition in the activity assay indicating 
it did not bind to the CysK active site. Both binding of CysK to CysE and CysK to the 
CysE C-terminus tetrapeptide did not show a change in fluorescence by a blueshift of 15 
nm (equivalent to partial closing of the CysK active site creating a change in the PLP 
fluorescence). Gel filtration CSC formation trials also show no elution peak 
corresponding to the CSC. These results suggest the CSC does not form within 
N. gonorrhoeae.  
 
Nanomolar concentrations of CysE (7 nM) and CysK (23 nM) (monomer concentrations) 
from E. coli have been used to form the CSC (Benoni et al., 2017b). This E. coli CSC 
had a reported dissociation constant (Kd) of 5 nM (Benoni et al., 2017b), indicating the 
CysE and CysK subunits have a strong affinity for each other, thus, strongly favouring 
CSC formation. A similar affinity was assumed of CysK and CysE from N. gonorrhoeae 
when planning the CSC experiments in this research. We have demonstrated that at more 
concentrated stocks (µM) of CysK and CysE, and lower concentrations of CysK and CysE 
C-terminus tail peptide (pmol), there is no indication of CSC formation, using multiple 
methods.  
 
It is possible that the CSC is completely unable to form in N. gonorrhoeae. Organisms 
that have lost the ability to form the CSC would no longer have a CSC inhibited CysK 
enzyme, allowing increased L-cysteine production. Due to the resulting, unregulated 
OAS consumption by CysK, down regulation of gene expression in sulphate acquisition 
genes would occur. Given the high demand for cysteine, to produce reducing compounds 
 
85 
such as glutathione (Seib et al., 2006), it may be advantageous for N. gonorrhoeae to not 
be capable of CSC formation.  
 
It is possible the lack of CSC formation is linked to the inability of N. gonorrhoeae to 
reduce sulphate to sulphide, and that the transcriptional regulator CysB controls two of 
the deleted genes from this pathway via operon control. N. gonorrhoeae OASS has the 
greatest homology to OASS-A isoform (CysK) as demonstrated via sequence alignment 
(Hicks & Mullholland, 2018). CysK utilises sulphide as a thiol donor, whereas CysM 
(OASS-B isoform) utilises directly imported thiosulphate. The inability of CysK to utilise 
thiosulphate and its ability to form the CSC where CysM cannot (Zhao et al., 2006) 
suggest that we would be able to from the CSC in N. gonorrhoeae. However, all 
experimental results suggest the contrary.  
  
Further experimentation is required to rule out CSC formation altogether. Peptide 
inhibition assays and fluorescent spectroscopy will be repeated using a decapeptide 
corresponding to the last 10 amino acids of the CysE C-terminal peptide to conclude 
whether our experiments showed no binding of the peptide due to it only being four amino 
acids in length. Addition of sulphide to the CSC formation in both gel filtration and 
fluorometric spectroscopy solutions will be trialled as sulphide is shown to promote 
reassociation of the CSC (Wirtz & Hell, 2006). Co-lysis of the CysK and CysE proteins 
will be attempted as this method has been established to produce stable complexes for 
functional and structural studies in challenging protein families including, the human 
steroid nuclear receptors (SNR) and the HIV-1 pre-integration complex (Levy et al., 
2016). Another bacterium, Brucella abortus was unable to form the CSC, despite the 
required residues being present in the CysE C-terminal tetrapeptide (Dharavath et al., 
2017). This was due to two CysK residues occupying the active site, thus, preventing the 
binding of the C-terminal tetrapeptide from CysE (Dharavath et al., 2017). Due to the 
active site missing from the N. gonorrhoeae CysK crystal structure, an improved 
resolution crystal structure of CysK is required to determine whether this is present in 
N. gonorrhoeae CysK as well.   
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3.4 Characterisation of the in vivo role of CysK by genetic 
manipulation of N. gonorrhoeae  
3.4.1 Essentiality of CysK and proposed role in vivo 
Neisseria species are particularly unique in that they have only one OASS isoform. This 
isoform has the greatest homology to CysK (OASS-A) and utilises sulphide for cysteine 
biosynthesis (Hicks & Mullholland, 2018). N. gonorrhoeae has an inability to reduce 
sulphate to sulphide and relies on thiosulphate for cysteine biosynthesis, a substrate which 
is usually utilised by the alternate OASS isoform CysM. This raises interesting questions 
regarding the role of CysK in N. gonorrhoeae. Whilst not being an essential gene for 
N. gonorrhoeae (Remmele et al., 2014), CysK has been shown to be important for 
colonisation of epithelial cells in N. meningitidis and when knocked out results in both 
decreased fitness and increased susceptibility to antibiotics (Turnbull & Surette, 2010; 
Capel et al., 2016).  
 
Many studies are underway with CysK being characterised as an antimicrobial target for 
other bacterial pathogens (Salsi et al., 2011; Franko et al., 2018; Joshi et al., 2019) and 
given deleting cysK from the genome has inflicted a decrease in fitness and increased 
susceptibility to antibiotics in other bacterial pathogens (Turnbull & Surette, 2010; Capel 
et al., 2016), coupled with rapid emergence of antimicrobial resistance in N. gonorrhoeae, 
determining the effects of this knockout in N. gonorrhoeae is vital to design of new 
antimicrobial agents. To determine whether CysK is essential in N. gonorrhoeae, cysK 
gene deletion by homologous recombination in N. gonorrhoeae using a plate 
transformation was trialled.  
3.4.2 N. gonorrhoeae cysK deletion construct for homologous recombination 
A DNA construct was designed and ordered as a geneblock from Twist Bioscience. The 
construct contained the N. gonorrhoeae kanamycin resistance gene (kanR) from (Ramsey 
et al., 2012) flanked by 150 base pairs of DNA sequence homologous to the DNA 
sequence upstream and downstream of cysK in the N. gonorrhoeae genome. Included in 
the construct was a promoter and terminator for the kanamycin resistance gene and the 





Figure 3.25: DNA construct of the N. gonorrhoeae cysK knockout with the kanamycin resistance gene 
(kanR). kanR seen in black. 150 bp of DNA sequence homologous to the DNA sequence upstream and 
downstream of the cysK gene in N. gonorrhoeae seen in grey. kanR promoter seen in green. kanR terminator 
seen in orange. DNA uptake sequences seen in purple. Figure created using Geneious Prime (Biomatter). 
 
Forward and reverse primers for the amplification of the entire DNA construct were 
designed and ordered as per section 2.14.2. PCR was conducted as per section 2.14.2 to 
amplify the DNA construct for transformation into N. gonorrhoeae. PCR product purity 
was tested via agarose gel electrophoresis (Figure 3.26) as per section 2.14.1. The gel 




Figure 3.26: PCR amplification and purification results of cysK KO construct run on a 1% agarose gel. 
Pre = PCR product before purification, Neg = negative control with Ultra Distilled water, Pure = purified 

















































3.4.3 Transformation of N. gonorrhoeae 
PCR products were prepared for plate transformations and 10 µl of PCR product 
(20 ng.µl-1) was spotted onto GCB agar plates in two places as per section 2.14.4. Piliated 
colonies from a fresh GCB agar plate were selected and streaked through the DNA circles 
for transformation. Single colonies from within these spotted DNA circles were streaked 
across GCB plates supplemented with 50 µg.ml-1 kanamycin and incubated as per section 
2.14.4. The plates were checked after a given 48 hours of incubation and no growth was 
found.   
 
The lack of growth on the kanamycin substituted plates presents three possible 
conclusions, (1) the gonorrhoea colonies had not successfully been transformed with the 
DNA PCR products and had therefore not integrated the kanamycin resistance gene into 
its genome, meaning it could not grow or survive on the kanamycin plate, (2) there was 
contamination present leading to growth of microbes other than N. gonorrhoeae that were 
therefore unable to transform and could not grow on the kanamycin substituted plates, or 
(3) N. gonorrhoeae could not grow on the kanamycin plates despite successful 
transformation and hence, uptake of the kanamycin resistance gene into its genome as the 
cysK gene is essential in N. gonorrhoeae.  
 
It was determined via colony PCR by Jolyn Pan that conclusion (2) was in fact correct. 
The colonies present on the initial New Yorker and GCB plates were tested via colony 
PCR and determined to be contaminants. Therefore, all solutions used from the beginning 
of PCR process were streaked on GCB plates. The elution buffer from the PCR 
purification kit (Roche-applied-science) was found to be contaminated. Therefore, cysK 
gene knockout testing was halted until a new purification kit could be obtained. 
3.4.4 cysK genomic deletion conclusions and future research  
No conclusions can be drawn from the cysK gene deletion experiments as the presence of 
contamination means we cannot be certain the colonies streaked onto the kanamycin 
substituted plates were N. gonorrhoeae.  
 
Thus, this experiment will be repeated in future research to determine the effect of 
knocking out cysK on the ability of N. gonorrhoeae to grow. It has been found that when 
a gene knockout is lethal to a bacterium, it is particularly useful to knockdown the gene, 
causing reduced activity rather than complete removal (Gillaspie et al., 2009). Therefore, 
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if the cysK knockout proves to be lethal, causing N. gonorrhoeae to not grow on the 
kanamycin substituted plates with no contaminants present, a knockdown of the cysK 
gene will be attempted. This will allow more effective study of the effect cysK has on the 
ability of N. gonorrhoeae to grow. It has previously been shown a tetracylcine-inducible 
promoter can be used in N. gonorrhoeae (Ramsey et al., 2012). This inducible promoter 
will be used to replace the cysK promoter in N. gonorrhoeae, allowing control of the 
activation of the gene using anhydrotetracycline which is effective at low concentrations 
without inhibiting growth of the bacterium (Ramsey et al., 2012). Combining the gene 
knockdown with testing cell adhesion and entry of N. gonorrhoeae into human cells using 
a human cell line, will potentially give further insight into the effect cysK has on the 




Conclusions and Future Research 
Neisseria gonorrhoeae is the causative agent of the sexually transmitted infection 
gonorrhoea (Hill et al., 2016; Wi et al., 2017). Rapid development of antibiotic resistance 
to every available antibiotic for its treatment over the last few decades, has led to 
increased demand for the development of new antimicrobial agents for future treatment 
of this disease (Wi et al., 2017). Targeting of amino acid biosynthesis is a promising new 
avenue for antimicrobial research. The amino acid cysteine’s biosynthetic pathway has 
been demonstrated to be vital for both pathogenicity and virulence in Neisseria species 
(Hatzios & Bertozzi, 2011; Takumi & Nonaka, 2016; Ren et al., 2017; Anderson et al., 
2019).   
 
N. gonorrhoeae encounters constant oxidative stress during infection. The ability of this 
obligate human pathogen to spread to new hosts is wholly dependent on its ability to 
mitigate and survive the oxidative stress produced by commensal Lactobacilli within the 
urogenital tract and the phagosomes of neutrophils encountered in host immune defence 
(Seib et al., 2006; Hill et al., 2016). Mitigation of this host derived oxidative stress relies 
on reducing systems within N. gonorrhoeae. Given the necessity of L-cysteine for protein 
folding, structure and function, formation of vital biomolecules such as biotin, 
co-enzyme-A, and iron-sulphur clusters and the synthesis of reducing agents, such as 
glutathione (Carmel-Harel & Storz, 2000; Kredich, 2008; Takumi & Nonaka, 2016; Hicks 
& Mullholland, 2018), the pathway for de novo synthesis of L-cysteine is an ideal target 
for developing new treatments for N. gonorrhoeae. However, both the function of the 
cysteine biosynthesis pathway and its regulation are not well understood in 
N. gonorrhoeae. In this thesis we have biochemically and structurally characterised one 
of the key cysteine biosynthetic enzymes, CysK. 
 
CysK is an O-acetylserine sulphydrylase that catalyses the final step in cysteine 
biosynthesis. CysK catalyses the condensation reaction of O-acetylserine with sulphide, 
to form L-cysteine (Rabeh & Cook, 2004; Joshi et al., 2019). The sulphur acquisition and 
cysteine biosynthesis pathways are regulated on multiple levels in response to the flux of 
sulphur concentrations (Wirtz et al., 2012). For CysK, this regulation is primarily carried 




This thesis presents the structure of CysK from N. gonorrhoeae at 2.49 Å. In our structure, 
the key PLP co-factor interacting residues are conserved. However, only part of the active 
site residues are conserved in the structure where the 223-GIGA-226 residues are not 
visible. This is a function of low resolution and the flexibility of the active site loop within 
the crystal structure. Obtaining a structure at a higher resolution with either substrate, S2- 
or OAS, bound in either the allosteric anion binding site found by (Tai et al., 2001) or the 
active site, respectively, will allow for better determination of the missing Glu204-Pro230 
loop from our structure, as well as a better indication of the mechanism of the enzyme. 
Each monomer within the homodimer, has an alternate conformation of PLP interacting 
residues. In monomer A, the 179-GTGGT-183 motif is blocking the PLP co-factor from 
binding, hence it is assumed this monomer is in an inactive conformation as CysK activity 
is PLP dependent. Conversely, the monomer D 179-GTGGT-183 motif supports the 
ability of the PLP co-factor to bind, indicating this monomer is in an active conformation. 
The presence of these alternate conformations within the homodimer, explains the 
positive cooperativity displayed within the enzyme’s kinetic analysis. We hypothesise 
binding of substrate into the active site of the active CysK monomer will cause a 
conformation change in the 179-GTGGT-183 loop of the inactive monomer, allowing 
PLP to bind, thus changing the inactive monomer to an active conformation. We have 
also determined the OASS isoform isolated from N. gonorrhoeae to be OASS-A/CysK 
as was hypothesised due to the higher sequence homology to CysK (Hicks & Mullholland, 
2018). However, for effective computational inhibitor screening, an understanding of 
kinetic mechanism is also vital. 
 
CysK from N. gonorrhoeae has O-acetylserine sulphydrylase activity, with kinetic 
constants (KM/Khalf) of 12.43 (KM) and 1.01 (Khalf), for sulphide and O-acetylserine, 
respectively, which are unique when compared with other CysK homologues. We 
demonstrate an allosteric sigmoidal (positive cooperativity) relationship is present for 
both substrates at low concentrations. This positive cooperativity is supported by the 
alternate conformations determined in the monomers of the CysK dimer within our crystal 
structure. The substrate sulphide also shows allosteric inhibition (partial inhibition), most 
likely due to the presence of an allosteric anion binding site determined by (Tai et al., 
2001). Interestingly, N. gonorrhoeae CysK was shown to be unable to utilise thiosulphate, 
even though the bacteria can grow thiosulphate as a sole sulphur source (Le Faou, 1984) 
and lack the OASS-B isoform that can utilise thiosulphate (Figure 4.1). This indicates the 
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CysK from N. gonorrhoeae is only capable of using sulphide as a substrate to produce 
cysteine and is therefore an OASS-A/CysK isoform and not a dual-functioning enzyme. 
The identification of the isolated OASS isoform from N. gonorrhoeae is also supported 
by our crystal structure analysis. Due to a genomic deletion and remnant pseudogenes 
corresponding to the sulphate assimilation pathway (Figure 1.2, red), N. gonorrhoeae is 
also incapable of reducing sulphate to sulphide to use in cysteine biosynthesis (Hicks & 
Mullholland, 2018). Therefore, we propose an alternative pathway for acquiring sulphide 
from a thiosulphate substrate, involving a sulphurtransferase enzyme, thiosulphate and 
























Figure 4.1: Sulphate transport and reduction pathways. Thiosulphate assimilation pathway in other bacteria 
shown in black on the left with dotted lines. Sulphate reduction pathway absent from N. gonorrhoeae shown 
in red on the right. Hypothesised sulphur acquisition in N. gonorrhoeae shown on the right in grey box. 
We were unable to get any indication of cysteine synthase complex formation using 
purified CysK and either CysE or the CysE C-terminus tetrapeptide from N. gonorrhoeae. 
Based on the presence of the isoleucine essential for CSC formation at the end of the 
C-terminal tail of CysE (Huang et al., 2005), and the flexible nature of the C-terminal tail 
(Oldham, 2020), we expected the CSC to form or give an indication of CysE 
tail/tetrapeptide binding to the CysK active site. The primary purpose of the CSC is to 
promote upregulation of the sulphate acquisition pathway as a response to low sulphur 
concentrations (Kumar et al., 2011). Given that N. gonorrhoeae is unable to reduce 
sulphate to sulphide, but is capable of growth using thiosulphate as a sole source of 
sulphur (Le Faou, 1984), there may be no evolutionary advantage to CSC formation. The 
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lack of CSC formation may provide an advantage to N. gonorrhoeae, in that it would 
allow continuous production of L-cysteine by CysK as it is no longer inhibited by the 
CysE C-terminus tail binding into its active site.  The complex is also unable to form in 
E. histolytica, and is attributed to the CysE forming a trimer rather than a hexamer 
conformation (Kumar et al., 2011).  Despite its inability to store glutathione, E. histolytica 
has high intracellular demands, which it relies on high cysteine concentrations to act as a 
reducing system to alleviate (Kumar et al., 2011). Conversely, N. gonorrhoeae is 
documented to have high intracellular concentrations of glutathione, however, both 
organisms would require large amounts of L-cysteine to maintain these high metabolite 
concentrations. (Remmele et al., 2014) suggests that de novo synthesis of cysteine is 
essential for N. gonorrhoeae and that L-cysteine/cystine importation alone, is not 
sufficient for meeting the L-cystine demands of N. gonorrhoeae.  
 
We were unable to conclusively define cysK from N. gonorrhoeae as essential as 
contamination interfered with the cysK gene deletion experiments. However, if the 
inability of the streaked N. gonorrhoeae to grow on the kanamycin supplemented plates, 
is seen in future repeats of this experiment, a cysK knockdown strain in N. gonorrhoeae 
strain will be created. The promoter of cysK in N. gonorrhoeae will be replaced with a 
controllable tetracycline-inducible promoter. This will confirm essentiality by in vitro 
growth experiments in the presence and absence of tetracycline. Combining the gene 
knockdown with testing cell adhesion and entry of N. gonorrhoeae into human cells using 
a human cell line, will potentially give further insight into the effect cysK has on the 
ability of N. gonorrhoeae to infect its obligate host.   
 
We have defined the isolated OASS isoform from N. gonorrhoeae as an OASS-A/CysK 
enzyme through both kinetic and structural analysis. Establishing this is a key point in 
understanding alternate sulphur acquisition pathways. N. gonorrhoeae can grow on 
thiosulphate as a sole source of sulphur and yet it lacks the enzyme capable of 
metabolising it. As we have established CysK is inactive at both low and high 
concentrations of thiosulphate. The apparent inability of the N. gonorrhoeae CysK and 
CysE enzymes to form the CSC is particularly interesting as many other organisms use 
this to regulate intracellular sulphur flux and cysteine biosynthesis. This suggests it is 
advantageous for N. gonorrhoeae to be unable to regulate either of these situations. 
However, there is also potential for an alternate mode of regulation. Establishing these 
alternate sulphur acquisition pathways will help in not only understanding of the 
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N. gonorrhoeae metabolic pathways but also to develop new potential targets for 
antimicrobial agents across a vast array of sulphur utilising bacteria.   
 
The results presented here represent a major leap forward in our understanding of both 
cysteine biosynthesis and sulphur acquisition in N. gonorrhoeae. These results are also 
the basis for future work in identifying potential CysK inhibitors through computational 
inhibitor screening. Computational inhibitor screening streamlines the inhibitor discovery 
process via the ability to screen hundreds of thousands of inhibitors, compared to only 
thousands of inhibitors using typical in vitro laboratory based screening. However, 
computational inhibitor screening also relies on detailed understanding of both the kinetic 
mechanism and high-resolution protein structures with and without substrates bound. 
Using the results presented here, computational inhibitor screening is underway by Dr 
Wanting Jiao at Victoria University of Wellington. Using the structure of CysK presented 
here and the published structure of M. tuberculosis CysK structure with PLP cofactor and 
a peptide inhibitor bound, we generated a structural model of PLP-bound CysK from 
N. gonorrhoeae for virtual screening. A library of 10 million commercially available 
compounds that contain drug like features were screened against CysK, using the virtual 
screening workflow in Schrodinger Suite. The screening has completed and produced 
1000 top scored compounds for further examination.  Using an established selection 
workflow, consisting of short MD simulations, 10-20 compounds will be selected for 
further in vitro testing. These will be tested using the assays developed in this thesis. In 
addition ongoing research to obtain CysK structures with OAS, S2- and Cl- bound will be 
attempted based on the crystallisation of CysK presented here.  
 
Overall, this research has contributed to a greater understanding of the sulphur acquisition 
pathway in N. gonorrhoeae which may help in elucidation of alternate sulphur acquisition 
pathways in other microbes. This research has also provided great insight into the 
previously uncharacterised enzyme, CysK and paved the way for the development of new 
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Appendix A: Cloning information for CysK 
A.1 Sequences for CysK (NGO_0340) 
CysK (NGO_0340) Neisseria gonorrhoeae (strain ATCC 700825/FA 1090) location 
 





















CysK peptide sequence. C-terminal HexaHis-tag (underlined) 318 residues. 



















pET28b description  
Table 4.1: Description of the pET28b Vector 
Vector Description 
pET28b E. coli expression vector, 5368 bps, 
N-terminal thrombin cleavage site, 
Kanamycin resistance, C and 
N-terminal His-tags, T7-promoter. 
  
GMO approval numbers:  
E. coli: GMD101146  
N. gonorrhoeae: GMD102338 
 
A.2 Luria Bertani (LB) Agar (1 L)  
Combine the following:  
5 g Peptone  
10 g NaCl  
5 g Yeast extract  
5 g Agar  
1 L of distilled water  
Autoclave at 121°C before use. 
  
LB Broth  











Appendix B: Protein purification, assay and kinetic 
information 
B.1 Purification buffers for CysK kinetics (Potassium phosphate) 
Table 4.2: Purification buffers for CysK kinetics (Potassium phosphate) 
 Chemical composition 
Lysis buffer 50 mM Potassium phosphate (pH 
8.0/7.0) 
200 mM NaCl 
20 mM Imidazole  
Elution buffer 50 mM Potassium phosphate (pH 
8.0/7.0) 
200 mM NaCl 
1 M Imidazole 
Gel filtration buffer 50 mM Potassium phosphate (pH 
8.0/7.0) 
100 mM NaCl 
 
B.2 Purification buffers for CysK crystallography (Tris) 
Table 4.3: Purification buffers for CysK crystallography (Tris) 
 Chemical composition 
Lysis buffer 50 mM Tris (pH 8.0) 
200 mM NaCl 
20 mM Imidazole  
Elution buffer 50 mM Tris (pH 8.0) 
200 mM NaCl 
1 M Imidazole 
Gel filtration buffer 50 mM Tris (pH 8.0) 









BioEnrich 650 SEC Calibration Curve 
 





L-cysteine Standard Curve 













































B.3 SDS-PAGE gel buffer compositions 
Quenching buffer (Q4)  
250 mM Tris (pH 6.8)  
20% glycerol (w/v)  
4% SDS (w/v)  
10% beta-2-mercaptoethanol (w/v)  
0.025% bromophenol blue (w/v) 
 
Tris-glycine SDS buffer 
25 mM Tris (pH 8.5) 
250 mM glycine 
0.1% SDS (w/v) 
 
Fairbanks staining solution 
0.05% coomasie blue  
25% isopropanol  
10% acetic acid  
 
Destaining solution  
10% acetic acid 
 
B.4 Required reagents and kinetic assay reagent compositions 
O-acetylserine (50 mM) 
91.8 mg O-acetyl-L-serine hydrochloride 
10 ml MQH2O 
 
O-acetylserine (5 mM) 
1 ml O-acetylserine (50 mM) 
9 ml MQH2O 
 
Sodium sulphide (50 mM) 
71.01 mg Sodium sulphide 





Sodium sulphide (5 mM) 
1 ml Sodium sulphide (50 mM) 
9 ml MQH2O 
 
Sodium thiosulphate (100 mM) 
158.11 g 
10 ml MQH2O 
Appropriate dilutions were made 
 
Acid Ninhydrin Reagent 
250 mg Ninhydrin 
6 ml Glacial acetic acid 
4 ml Concentrated hydrochloric acid (10 M) 
 
Trichloroacetic acid (20% v/v) 
2 g Trichloroacetic acid 
10 ml MQH2O  
 
PLP (Pyridoxal 5’-phopshate, 2mM) 
4.94 mg PLP 
10 ml MQH2O 
 
MOPs buffer (100mM, pH 7) 
2.093 g MOPs 
Make up to 10 ml MQH2O 
 
DTT (Dithiothreitol)  
308.5 mg DTT 
Make up to 10 ml with MOPs buffer 
pH to 7 with NaOH 
 
CysE C-terminus tail four peptide inhibitor (3820 pmol, 2 mg.ml-1) 
2 mg CysE four peptide tail 




CysE C-terminus tail four peptide inhibitor (382 pmol, 0.2 mg.ml-1) 
20 µL of 2 mg.ml-1 CysE C-terminus four tail four peptide inhibitor 
180 µL Potassium phosphate gel filtration buffer 
 
CysE C-terminus tail four peptide inhibitor (38.2 pmol, 0.02 mg.ml-1) 
20 µL of 0.2 mg.ml-1 CysE C-terminus four tail four peptide inhibitor 
180 µL Potassium phosphate gel filtration buffer 
 
CysE C-terminus tail four peptide inhibitor (3.82 pmol, 0.002 mg.ml-1) 
20 µL of 0.02 mg.ml-1 CysE C-terminus four tail four peptide inhibitor 
180 µL Potassium phosphate gel filtration buffer 
 
L-cysteine (50mM) 
60.58 mg L-cysteine 
10 ml MQ H2O 
pH to 2.0 
 
L-cysteine (5 mM) 
1 ml of 50mM L-cysteine 
9 ml MQ H2O 
 
B.5 Raw assay data 












Appendix C: PCR and Gene Knockouts 
Agarose gel 
50 µl 1xTAE Buffer 
0.5 g Agarose 
Microwave (30 second bursts till dissolved) 
Cool with running water over flask 
4 µl Red Safe Stain 
Pour into OWL electrophoresis gel caster (ThermoFisher Scientific) 
 
TAE Buffer (50x)  
242 g Tris-base 
700 ml MQ H2O 
57 ml 100% glacial acetic acid 
100 ml 0.5 M EDTA (pH 8.0) 
Make up to 1 L with MQ H2O 
 
TAE Buffer (1x) 
50 ml of 50x TAE buffer 
Make up to 1 L with MQ H2O 
 
EDTA (0.5 M) 
93.05 g EDTA disodium salt  
400 ml MQ H2O 
pH to 8.0 with NaOH 
Make up to 500 ml with MQ H2O 
 
DNA loading buffer (6x)  
3ml 30% (v/v) Glycerol 
25mg 0.25% (w/v) Bromophenol Blue 
25mg 0.25% (w/v) Xylene Cyanol FF 








36.25 g GCBase 
1.25 g Agar 
1 L MQ H2O 
Split into two 500 ml Schott bottles 
Autoclaved 
500 µl of 50 mg.ml-1 kanamycin added to one Schott bottle 
Poured into petri dishes and set for ~20 mins 
Set plates stored at 4º C 
 
Invitrogen 1kb+ DNA ladder 
 












Appendix D: Crystallisation and Structure solving information 
D.1 Contents of the asymmetric unit for CysK 
 
Figure 4.5: Contents of the asymmetric unit for CysK model. Space group P1211. Waters are seen as red 
crosses. Figure generated in PyMOL. 
 
D.2 Initial input settings for phenix.autobuild 
 











D.3 Final input settings for phenix.autobuild 
 
Figure 4.7: Screenshot of initial input settings for phenix.autobuild used for building the final model of 
CysK 
 
D.4 CysK structural files 




D.5 CysK chain statistics 
Table 4.4: CysK structure statistics for each monomer in the ASU.  
Chain Residue chain built Residues missing Total built 
A Ile3-Pro143 Ala150-
Glu204 Pro230-
Tyr296 
51 261/312 
B Ile3-Pro143 
Asn151-Glu204 
Pro230-Tyr296 
52 260/312 
C Ile3-Pro143 
Asn151-Gly206 
Tyr238-Leu292 
64 248/312 
D Ile3-Pro143 
Asn151-Ala207 
Tyr238-Tyr296 
63 249/312 
 
